#### **Supplementary Materials**

Brain heterogeneity in 1,792 individuals with schizophrenia: effects of illness stage, sites of origin and pathophysiology

Yuchao Jiang, et al

#### This supplementary material includes as follows:

#### Part 1: Methods

- Method S1. Null model and permutation test.
- Method S2. Transcriptomic analysis.
- Method S3. Neurotransmitter receptors and transporters analysis.
- Method S4. Network diffusion model.
- Method S5. Brain connectome estimation.

#### Part 2: Results

- Result S1. Regional variability in females and males.
- Result S2. Identifying regions that are 'invariant' in gray matter reduction.
- Result S3. Association between PD- map and human brain gene map.
- Result S4. Association between regional variability in schizophrenia and neurotransmitter systems.
- Result S5. Network-based diffusion modeling at group-level and individual-level.

#### Part 3: Discussion

Discussion S1. Lower variability in schizophrenia is inconsistent in prior studies.

#### Part 4: Supplementary Tables

- Table 1. Sample demographics by participating cohort.
- Table 2. Dataset-specific information.
- Table 3. Mean difference in regional gray matter volume measures.
- Table 4. Variability difference in regional gray matter volume measures.
- Table 5. Proportion of patients with greater deviation in regional gray matter volume measures.
- Table 6. Spatial correlation results.
- Table 7. Correlation between brain variability map in schizophrenia and neurotransmitter map.
- Table 8. Network diffusion model performances on estimating cross-sectional gray matter differences in schizophrenia.
- Table 9. Model performance with each brain region as the seed of network diffusion model.

Table 10. Network diffusion model (NDM)-based 'spatial' phenotypes in schizophrenia population.

<u>Table 11.</u> Regional comparisons of gray matter volume between each spatial phenotype in schizophrenia and healthy controls.

#### Part 5: Supplementary Figures

Supplementary Fig.1. High consistency between the case-control difference (i.e., effect size) brain map that sourced from (a) discovery sample and (b) validation sample.

Supplementary Fig.2. Partial least squares (PLS) correlation analysis between individual deviation and human brain gene expression data.

Supplementary Fig.3, Performance of network diffusion model (NDM) on estimating cross-sectional GMV differences in group-level patients with schizophrenia.

# Method S1. Null model and permutation test

### 1. Permutation statistical test

To examine whether the variability of regional volume (InCVR) was significantly different between the patient group and healthy control group, we used a permutationbased test. First, we computed the true InCVR based on the true labels of patient or control. Second, a permutation step was conducted by randomly swapping labels of observation, and generated a possible InCVR. The permutation process was repeated 1,000 times, and thus generated a distribution of the possible values under the null hypothesis that observations are exchangeable. The distributions of possible values among 1,000 permutations in each brain region exhibit normal distributions. According to the location of true value in the distribution of the possible values, the P-value (two-sided) was estimated to be how probable such observations would be if the null hypothesis is true.

### 2. Spatial permutation test

We utilize the spin test, specifically the spatial permutation test, to address spatial autocorrelation when assessing the correspondence between the brain epicenter map and other maps [1, 2]. This approach is increasingly acknowledged as a leading method for examining spatial concordance in human brain mapping and has been extensively applied in numerous neuroimaging investigations [3-5].

A recent study has conducted a comprehensive analysis of ten null models for evaluating the correspondence of brain maps in neuroimaging research [6]. The findings reveal that naive null models, which neglect to preserve spatial autocorrelation, consistently lead to higher false positive rates and unrealistically liberal statistical estimates [6]. Additionally, the study demonstrates significantly enhanced performance and decreased error rates in null models that account for spatial autocorrelation compared to spatially-naive models [6]. In summary, based on these comprehensive comparisons, there is a strong recommendation for the adoption of spatial permutation null models [6].

The spin test employed here is a spatial permutation method based on angular permutations of spherical projections at the cortical surface. Critically, the spin test preserves the spatial covariance structure of the data and as such is far more conservative than randomly shuffling locations, which destroys the spatial covariance structure and produces an unrealistically unconservative null distribution. A previous study indicated that null models tend to converge and yield stable statistical estimates after generating approximately 100 to 500 nulls. Here, we generated 10,000 random spatial rotations (i.e., spins) of the brain regions to generate a null distribution. Then, the  $p_{spin}$  values were obtained according to the location of true value within the null models.

# Method S2. Transcriptomic analysis

### Transcriptomic data

The Allen Human Brain Atlas dataset (AHBA) (<u>http://human.brain-map.org</u>) provides gene expression data of brain tissue samples obtained from six postmortem human brains, which allow to investigate the association between transcriptome and regional variability and individual deviation in schizophrenia. After preprocessing AHBA data using the *abagen* [7], regional microarray expression data were extracted using the same regions with above GMV measurements. To get stably expression, genes exhibiting a low level of similarity across donors (*r*<0.2) were removed, resulting in a final set of 12,668 genes. Since only two donors have available data in the right hemisphere, we used the left hemisphere gene expression data for the following analyses.

### Partial least squares correlation analysis

Partial least squares (PLS) correlation analysis [8] was used to examine the association of gene expression levels for all 12,668 genes with regional variability and individual deviation in schizophrenia. First, regional-wise gene expression data were used as predictor variables, and regional variability (InCVR) or individual deviation (PD- or PD+) values were used as the response variables in PLS correlation. The first component of PLS (PLS1) indicated a strong spatial correlation with response variables. To correct spatial autocorrelation, spatial permutation test (*spin* test) was employed, as detailed in the **Supplementary Materials**. A boostrapping method was conducted to estimate the variance in the weight of each gene in the PLS analysis. The ratio of the weight of each gene to its bootstrap standard error (iterations=1000) was utilized to compute a Z score, allowing for the ranking of genes according to their contribution to PLS1 [9]. The list of genes with an FDR corrected p<0.05 was extracted for subsequent enrichment analysis.

### Gene enrichment analysis

Gene enrichment analysis was performed using Metascape [10]. The genes list generated from PLS analysis were input into the Metascape analysis. Pathway and process enrichment analysis was carried out with the ontology sources: KEGG Pathway, GO Biological Processes, Reactome Gene Sets, Canonical Pathways, CORUM, WikiPathways, and PANTHER Pathway. P values were calculated based on the cumulative hypergeometric distribution. The Benjamini-Hochberg procedure was used to calculate q values account for multiple tests [11].

# Method S3. Neurotransmitter receptors and transporters analysis

We investigated the relationships between regional variability (and individual deviations) in schizophrenia and neurotransmitter systems across all brain regions. To this end, we used whole-brain positron emission tomography (PET) images across a cohort over 1200 healthy individuals, sourced from multiple studies (accessible at <a href="https://github.com/netneurolab/hansen\_receptors">https://github.com/netneurolab/hansen\_receptors</a>). Each of previous studies provided the mean tracer map across subjects, with details including the associated receptor/transporter, tracer used, number of healthy participants, age, and reference with full methodological details, as summarized in a previous study [5]. Using these data, we obtained a comprehensive profile of neurotransmitter receptors and transporter densities in brain, including 19 distinct neurotransmitter receptors and transporters across nine different neurotransmitter systems. Specifically, PET images were initially registered to a normalization template (MNI-ICBM 152 nonlinear 2009 template) and subsequently parcellated into 68 cortical and 16 subcortical regions, using the same atlases with the gray matter volume measurement. These images represent estimates proportional to receptor densities and are therefore referred to simply as 'density' here. Subsequently, the density values of each neurotransmitter receptor/transporter were transformed into z-scores across all regions. This process yielded a 84x19 matrix representing relative neurotransmitter receptor/transporter densities across 19 different neurotransmitter systems, including dopamine (D<sub>1</sub>, D<sub>2</sub>, and DAT), norepinephrine (NAT), serotonin (5-HT<sub>1a</sub>, 5-HT<sub>1b</sub>, 5-HT<sub>2a</sub>, 5-HT<sub>4</sub>, 5-HT<sub>6</sub>, and 5-HTT), acetylcholine, glutamate (mGluR<sub>5</sub> and NMDAR), gamma-aminobutyric acid (GABAa), histamine, cannabinoid, and opioid. Next, Spearman correlation analysis was conducted to explore the spatial relationship between the regional variability map (and individual deviation maps) in schizophrenia and the neurotran

# Method S4. Network diffusion model

We employed a classical algorithm known as the NDM [12] to simulate the specific spatial patterning of GMV alterations through a putative diffusion process within a brain network. It enabled us to identify potential focal points of brain structural alteration. NDM has been applied in schizophrenia, revealing specific spatial patterning of GMV changes across different stages of psychosis [13].

### 2.8.1 Brain connectome estimation

Brain connectivity data were derived from MICA-MICs dataset [14]. Normative brain connectome architectures were estimated from diffusion MRI, resting-state functional MRI, and T1-weighted MRI acquired in an independent sample of 50 healthy participants (23 women; mean age=29.54±5.62 years). Multi-modal MRI data were processed using the open-source pipeline, micapipe (<u>https://micapipe.readthedocs.io</u>). We obtained multi-modal connectomes including structural connectivity (SC), functional connectivity (FC) and morphological covariance connectivity (MC), generated from the diffusion scans, resting-state functional scans and T1-weighted scans separately. A detailed description of the methods to generate the connectomes is described in **Supplementary Materials**. All connectomes were generated from the 68 cortical regions in the Desikan-Killian atlas [15] and 18 subcortical regions, for consistency with GMV measurements. Group-averaged connectomes across participants were used as the reference brain connectivity for the following NDM.

### 2.8.2 Network diffusion modeling

We used NDM to test whether GMV change spreads through the brain via a process of diffusion. In NDM, pathological progression is assumed to be a diffusive propagation between connected brain regions, as described by the equation:

$$f(t) = e^{\beta H t} f_0$$

Where *t* is the model diffusion time, f(t) is a vector describing the pattern of diffusion in each region at time *t*,  $\beta$  is a diffusivity constant, and *H* is the Laplacian of the brain network, and  $f_0$  is the initial distribution of pathology at *t*=0.

We used a seed-searching approach to detect the optimal seed for modeling. Specifically, we repeatedly initialized the model by using each of the 82 regions as the starting seed. In this process, the initial state  $f_0$  was set to 1 for the seed region (bilateral) and 0 for all other regions [12]. During each initialization, with a constant value of  $\beta$ =1, we estimated the diffusion f(t) at all other regions from time t= 1 to 50 [12]. We further determined whether such a diffusion process from specific seed region matched GMV changes from empirically observed data. We calculated the Spearman r values between the spatial pattern of empirically observed GMV changes and the NDM estimated patterns. Spatial permutation test (i.e., *spin* test) was utilized to address spatial autocorrelation correction. An acceptable performance by NDM was defined as corrected  $p_{spin}$ <0.001. In this way, it was able to determine the optimal connectome type and optimal seed region for NDM simulation of both group-level and individual-level GMV changes.

# Method S5. Brain connectome estimation

Brain connectivity data were derived from MICA-MICs dataset [14]. Normative brain connectome architectures were estimated from diffusion MRI, resting-state functional MRI, and T1-weighted MRI acquired in an independent sample of 50 healthy participants (23 women; mean age=29.54±5.62 years). Multi-modal MRI data were processed using the open-source pipeline, micapipe (<u>https://micapipe.readthedocs.io</u>). We obtained multi-modal connectomes including structural connectivity (SC), functional connectivity (FC) and morphological covariance connectivity (MC), generated from the diffusion scans, resting-state functional scans and T1-weighted scans separately.

### 1. Structural connectivity (SC)

Structural connectomes were constructed using MRtrix from pre-processed diffusion MRI data [16]. Anatomically-constrained tractography was performed using tissue types segmented from each participant's pre-processed T1-weighted (T1w) images, which were registered to native DWI space [17]. Multi-shell and multi-tissue response functions were estimated, followed by constrained spherical deconvolution and intensity normalization [18]. A tractogram comprising 40 million streamlines (with a maximum tract length of 250 and a fractional anisotropy cutoff of 0.06) was generated. Spherical deconvolution informed filtering of tractograms (SIFT2) was applied to reconstruct whole brain streamlines weighted by cross-sectional multipliers [19]. The reconstructed streamlines were then mapped to each parcellation scheme (both cortical and subcortical), which were also aligned to DWI space. The connection weights between nodes were defined based on the weighted streamline count.

### 2. Functional connectivity (SC)

Resting-state functional MRI time series, were firstly mapped to subject-specific surface models, and subsequently averaged within cortical parcels. The subcortical parcellation was also aligned to each subject's native functional MRI volume space and used to average time series within each node. Individual functional connectomes were generated by cross-correlating all nodal time series. Correlation coefficient values underwent Fisher's r-to-z transformations.

### 3. Morphological covariance connectivity (MC)

Morphological covariance network was generated from T1-weighted images in the dataset. The FreeSurfer processing pipeline was used to calculate the cortical volume values for each region in the Desikan-Killiany atlas and subcortical volume. Linear regression was performed for each region to remove the effects of age, gender, and TIV; the residuals of this regression were used for a Pearson's correlation analysis. Connectivity weights were defined as the z transformation of Pearson's R value across subjects; Regions are considered connected if their regional volumes co-vary across subjects.

# **Result S1. Regional variability in females and males**

We also calculated regional InCVR in female patients and male patients separately. Differences of InCVR between patients and healthy controls are provided in the below table 1.

In all people (females and males), significant greater InCVR (p<0.05, FDR corrected), compared with healthy controls, was found in 50 regions in the whole patient group, at a much greater frequency in the first-episode group (73 regions), compared to the chronic group (28 regions; Chi-square test, p=5.0×10<sup>-13</sup>).

In females, we found that compared with healthy controls, significant greater InCVR (p<0.05, FDR corrected) was found in 17 regions in the whole patient group, at a much greater frequency in the first-episode group (65 regions), compared to the chronic group (5 regions; Chi-square test, p=2.7×10<sup>-21</sup>).

In males, we found that compared with healthy controls, significant greater InCVR (p<0.05, FDR corrected) was found in 26 regions in the whole patient group, at a much greater frequency in the first-episode group (54 regions), compared to the chronic group (20 regions; Chi-square test, p=9.5×10<sup>-8</sup>).

Group 1	Group 2	Number of regions with higher InCVR in group 1 compared to group 2	Number of regions with lower InCVR in group 1 compared to group 2
Schizophrenia all (N=1792)	HC all (N=1523)	50	0
FES drug-naive all (N=478)	HC all (N=1523)	73	0
Chronic all (N=398)	HC all (N=1523)	28	4
Schizophrenia female (N=760)	HC female (N=698)	17	0
FES drug-naive female (N=239)	HC female (N=698)	65	0
Chronic female (N=139)	HC female (N=698)	5	10
Schizophrenia male(N=1032)	HC male (N=825)	26	0
FES drug-naive male (N=239)	HC male (N=825)	54	0
Chronic male (N=259)	HC male (N=825)	20	3

#### Table 1. Differences of InCVR between patients and healthy controls in females and males.

FES, first-episode; HC, healthy control.

# Result S2. Identifying regions that are 'invariant' in gray matter reduction

We derived a score [i.e., rank(ES/CVR)] by ranking ratio between the effect size (ES) in group-level mean difference and variability for each region to identify regions that are 'invariant' in gray matter reduction. A small CVR value represents a low variability in gray matter volume (that is, a large 1/CVR represents an 'invariant' in gray matter volume). A high ES value represents a large reduction of gray matter volume in patients relative to healthy controls. The table 2 in below shows the top 20 regions with largest ES/CVR value. It shows that the left insula, supramarginal and right pracentral exhibit 'invariant' in gray matter reduction.

Region	ES/CVR	Rank(ES/CVR)	Rank(ES)	Rank(1/CVR)
L_hippocampus	0.333	1	1	78
R_hippocampus	0.311	2	2	70
L_insula	0.282	3	7	12
L_precentral	0.279	4	4	39
R_thalamus	0.274	5	3	80
L_superiorfrontal	0.261	6	5	71
R_fusiform	0.260	7	8	47
L_postcentral	0.259	8	10	24
L_superiortemporal	0.256	9	9	56
R_insula	0.251	10	11	29
L_thalamus	0.246	11	6	81
L_supramarginal	0.241	12	16	10
L_amygdala	0.231	13	17	31
L_lateraloccipital	0.231	14	19	25
R_inferiortemporal	0.229	15	15	48
L_fusiform	0.228	16	13	67
R_paracentral	0.227	17	30	4
R_superiorfrontal	0.226	18	14	63
R_inferiorparietal	0.226	19	24	30
R_transversetemporal	0.226	20	21	37

## Table 2. The top 20 regions with largest $\ensuremath{\mathsf{ES/CVR}}$ value.

# Result S3. Association between PD- map and human brain gene map.

There was a spatial association (r=0.391, p=0.022) between the PD- map and gene PLS1 map (see **Supplementary Figure 2**). A total of 1,572 significant genes (FDR p<0.05) remained (**Supplementary Figure 2c**), and their enrichment biological processes are shown in the **Supplementary Figure 2d**. In cell type signatures, these genes were enriched in the microglia and astrocytes in the prefrontal cortex, as well as midbrain neuron types (**Supplementary Figure 2e**). In addition, these enriched genes were also related to human brain disorders such as the movement disorders, nystagmus, and hyporeflexia (**Supplementary Figure 2f**).

Possible interpretation for PD- : By mapping the proportion of patients with a moderate deviation in GMV reduction, PD- can be hypothesized as a common representation across individuals with schizophrenia, which reflects brain biology involving in ageing, cognitive decline and cortical volume loss. The strongest peak of PD- map was located at bilateral thalamus, indicating that the thalamus is probably one of the most frequently affected regions across all people with schizophrenia. This may be due to thalamic function and connection. Specifically, thalamus plays an important role in integrating sensory input from external environment [20]. It also acts as an interface of body-mind in stress response [21], which is impaired in patients with schizophrenia [22, 23]. Thalamus has widespread connections to different cortical areas, subcortical regions and cerebellum [24]. As a hub, it is suggested to probably be more susceptible to affecting other regions, or be affected. Furthermore, genes associated with PD- were primarily enriched in the astrocytes and microglia in the prefrontal cortex. Interestingly, our finding supports a novel perspective from a recent study reporting that schizophrenia and ageing have a common neurobiological basis, and astrocytes is involved in the multiple kinds of pathophysiology of schizophrenia [25]. These findings suggest that the PD- map can capture certain shared biological signature referring to pathophysiological 'brain ageing' that are most common across people with schizophrenia.

## **Result S4.** Association between regional variability in schizophrenia and neurotransmitter systems.

We found significant correlations between brain variability map and neurotransmitter maps (**Supplementary Table 7**). Specifically, the InCVR map in schizophrenia spatially correlated with the opioid map (MOR, r=0.331, p=0.036). The PD- map was correlated with neurotransmitter maps in serotonin (5-HT<sub>2a</sub>, r=0.299, p=0.006) and dopamine (DAT, r=-0.242, p=0.022). Additionally, there were significant negative correlations between the PD+ and serotonin 5-HT<sub>1A</sub>, receptors (r=-0.296, p=0.036) while positive correlations seen with dopamine D<sub>1</sub> receptor (r=0.337, p=0.004).

## **Result S5.** Network-based diffusion modeling at group-level and individual-level.

We employed the NDM to simulate the possible processes (i.e., spatial 'spreading' pattern) of GMV alteration across brain regions. We assessed the model performance by using the Spearman correlation coefficient between the spatial map of group-level GMV difference (i.e., effect size map) and the NDM simulated map. We found that the GMV difference in patients was successfully simulated by using the NDM (**Supplementary Figure 2a and Supplementary Table 8**). We observed significant spatial correlations between observed values and simulated values for three models: NDM<sub>MC</sub> (*r*=0.789, *p*=1.0×10<sup>-18</sup>), NDM<sub>SC</sub> (*r*=0.547, *p*=1.1×10<sup>-7</sup>), and NDM<sub>FC</sub> (*r*=0.669,  $p=6.2\times10^{-12}$ ) (**Supplementary Figure 3a**). Consistent with discovery sample, the spatial correlations were replicated in the validation sample (**Supplementary Figure 3a**). Temporal lobe regions (mainly the hippocampus) were consistently identified as the optimal source seed (**Supplementary Figure 3b**), across the three models,

and across subsamples at different illness stages (first-episode, drug-naïve, and chronic) (**Supplementary Table 8**). In the validation data, additional optimal seeds were found in the frontal pars opercularis region by the NDM<sub>MC</sub>. In both subsamples with first-episode and drug-naïve patients, additional optimal seeds were found in the thalamus by the NDM<sub>SC</sub> (**Supplementary Table 8**). A full list is provided in **Supplementary Table 9** to show the model performances with each region being the starting point of NDM. This indicates that 'spreading' atrophy patterns starting at hippocampus, pars opercularis and thalamus are likely explanations for the variability seen in patients.

At the individual-level, we employed the NDM to estimate the individual deviations in GMV differences in each patient. We found that the NDM can achieve an accepted performance (*p<sub>spin</sub>*<0.001) in the consistency between estimated values and observed values for 72.1% patients (SZ<sub>NDM</sub>, n=1,292) (**Supplementary Table 10a**). For these SZ<sub>NDM</sub> patients, we further classified them into several subgroups based on the heterogeneity in optimal seed locations. The seed of NDM may serve as the 'disease epicenters' that lead to network-spreading patterns of brain structural changes during regional pathological processes [13]. The heterogeneity of pathological processes may be uncovered by detecting the optimal seeds applying the NDM on individual patient's data. Herein, patients were assigned to subgroups, termed as 'spatial' phenotypes, based on the spatial locations of the seeds (**Supplementary Table 10b**). **Figure 4** shows specific spatial patterns of GMV change in each spatial phenotype, which are labelled as 'temporal cortex', 'frontal cortex', 'occipital cortex', 'somatosensory cortex', 'cingulate-insula', 'basal ganglia' or 'thalamus' phenotypes. It shows that 'temporal cortex' and 'frontal cortex' phenotypes account for the highest proportion of patients, reaching 24.2% and 13.6% respectively. **Supplementary Table 11** shows regional comparison of GMV between patients and controls for each spatial phenotype. Together, we show the existence of neuroanatomically distinct phenotypes, which are characterized with differential spatial patterns of gray matter alterations in schizophrenia.

# Discussion S1. Lower variability in schizophrenia is inconsistent in prior studies.

The regional distribution of lower variability in schizophrenia (i.e., homogeneity) has been inconsistent in prior studies [26-28]. Previous study reported a lower variability in the anterior cingulate volume [26] but this was not replicated in two other recent works [27, 28]. In contrast, a recent work found significantly lower variability in the left parahippocampal region [27]. Our data did not show reduced variability in any regional volume in first-episode patients, but in established cases, variability is lower in the left parahippocampal and specific occipital regional volumes. Notably, occipital regions exhibit higher volume, indicating that over time some shared tissue increase may occur among patients, irrespective of the heterogenous origins of the tissue reduction, supporting a dynamic reorganization effect [29]. Importantly, we find that higher inter-individual variability is associated with a reduction in GMV, but not with the increase seen across the brain, supporting the notion that compensatory activity may occur over time [30]. Taken together, our work provides a comprehensively evaluation on the inter-patient variability of structural brain measures, summarizing consistent/inconsistent findings in heterogeneity and homogeneity of neuroanatomical alteration in schizophrenia, compared with previous knowledge [26-28].

#### References

- 1. Alexander-Bloch, A.F., et al., *On testing for spatial correspondence between maps of human brain structure and function.* Neuroimage, 2018. **178**: p. 540-551.
- 2. Vasa, F., et al., *Adolescent Tuning of Association Cortex in Human Structural Brain Networks.* Cereb Cortex, 2018. **28**(1): p. 281-294.
- 3. Markello, R.D., et al., *neuromaps: structural and functional interpretation of brain maps.* Nat Methods, 2022. **19**(11): p. 1472-1479.
- 4. Vasa, F. and B. Misic, *Null models in network neuroscience.* Nat Rev Neurosci, 2022. 23(8): p. 493-504.
- 5. Hansen, J.Y., et al., *Mapping neurotransmitter systems to the structural and functional organization of the human neocortex.* Nat Neurosci, 2022. **25**(11): p. 1569-1581.
- 6. Markello, R.D. and B. Misic, *Comparing spatial null models for brain maps.* Neuroimage, 2021. **236**: p. 118052.
- 7. Arnatkeviciute, A., B.D. Fulcher, and A. Fornito, *A practical guide to linking brain-wide gene expression and neuroimaging data.* Neuroimage, 2019. **189**: p. 353-367.
- 8. Abdi, H., *Partial least squares regression and projection on latent structure regression (PLS Regression).* Wiley interdisciplinary reviews: computational statistics, 2010. **2**(1): p. 97-106.
- 9. Morgan, S.E., et al., *Cortical patterning of abnormal morphometric similarity in psychosis is associated with brain expression of schizophrenia-related genes.* Proc Natl Acad Sci U S A, 2019. **116**(19): p. 9604-9609.
- 10. Zhou, Y., et al., *Metascape provides a biologist-oriented resource for the analysis of systems-level datasets.* Nat Commun, 2019. **10**(1): p. 1523.
- 11. Hochberg, Y. and Y. Benjamini, *More powerful procedures for multiple significance testing.* Stat Med, 1990. **9**(7): p. 811-8.
- 12. Raj, A., A. Kuceyeski, and M. Weiner, *A network diffusion model of disease progression in dementia.* Neuron, 2012. **73**(6): p. 1204-15.
- 13. Chopra, S., et al., *Network-Based Spreading of Gray Matter Changes Across Different Stages of Psychosis.* JAMA Psychiatry, 2023. **80**(12): p. 1246-1257.
- 14. Royer, J., et al., *An Open MRI Dataset For Multiscale Neuroscience.* Sci Data, 2022. **9**(1): p. 569.
- 15. Desikan, R.S., et al., *An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest.* Neuroimage, 2006. **31**(3): p. 968-80.
- 16. Tournier, J.D., et al., *MRtrix3: A fast, flexible and open software framework for medical image processing and visualisation.* Neuroimage, 2019. 202: p. 116137.
- 17. Smith, R.E., et al., *Anatomically-constrained tractography: improved diffusion MRI streamlines tractography through effective use of anatomical information*. Neuroimage, 2012. **62**(3): p. 1924-38.
- 18. Jeurissen, B., et al., *Multi-tissue constrained spherical deconvolution for improved analysis of multi-shell diffusion MRI data.* Neuroimage, 2014. 103: p. 411-426.
- 19. Smith, R.E., et al., *SIFT2: Enabling dense quantitative assessment of brain white matter connectivity using streamlines tractography.* Neuroimage, 2015. **119**: p. 338-51.
- 20. Wolff, M., et al., *A thalamic bridge from sensory perception to cognition.* Neurosci Biobehav Rev, 2021. **120**: p. 222-235.
- 21. Reinelt, J., et al., *Acute psychosocial stress alters thalamic network centrality.* Neuroimage, 2019. **199**: p. 680-690.
- 22. Howes, O.D., et al., *The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia*. Biol Psychiatry, 2017. **81**(1): p. 9-20.
- 23. Howes, O.D. and E.C. Onwordi, *The synaptic hypothesis of schizophrenia version III: a master mechanism.* Mol Psychiatry, 2023.
- 24. Shine, J.M., et al., *The impact of the human thalamus on brain-wide information processing.* Nat Rev Neurosci, 2023. **24**(7): p. 416-430.
- 25. Ling, E., et al., *A concerted neuron-astrocyte program declines in ageing and schizophrenia.* Nature, 2024. **627**(8004): p. 604-611.
- 26. Brugger, S.P. and O.D. Howes, *Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia: A Meta-analysis.* JAMA Psychiatry, 2017. **74**(11): p. 1104-1111.
- 27. Omlor, W., et al., *Estimating multimodal brain variability in schizophrenia spectrum disorders: A worldwide ENIGMA study.* bioRxiv, 2023: p. 2023.09.22.559032.
- 28. Alnaes, D., et al., Brain Heterogeneity in Schizophrenia and Its Association With Polygenic Risk. JAMA Psychiatry, 2019. 76(7): p. 739-748.

- 29. Guo, S., et al., *Dynamic cerebral reorganization in the pathophysiology of schizophrenia: a MRI-derived cortical thickness study.* Psychol Med, 2016. 46(10): p. 2201-14.
- 30. Palaniyappan, L., et al., *Structural covariance and cortical reorganisation in schizophrenia: a MRI-based morphometric study.* Psychol Med, 2019. **49**(3): p. 412-420.

### Supplementary Table 1. Sample demographics by participating cohort.

N		N Mean Age Mean Age		Mean Age	F/M	F/M		DANIOO Destification (Lassala	DANOO Ne setti se Oslassela	DANSS Conoral Subasala	DANCO Total Coord
Conort	Case	Control	(SZ)	(HC)	(SZ)	(HC)	Mean Duration Of Illness (years)	PANSS Positive Subscale	PANSS Negative Subscale	PANSS General Subscale	PANSS Total Score
CN-Shanghai1	361	267	24.3±8.0	24.0±4.9	167/194	144/123	0.9±1.4	20.2±5.7	15.4±7.4	38.1±8.1	73.7±15.7
CN-Shanghai2	159	133	24.9±7.0	23.7±5.9	84/75	67/66	1.4±2.0	23.7±5.3	18.1±6.8	41.4±7.2	83.2±13.7
CN-Shanghai3	42	23	29.9±7.4	31.2±5.9	23/19	12/11	6.6±5.7	19.9±3.1	18.4±6.4	33.1±4.9	71.4±9.0
CN-Harbin	49	0	26.7±8.1	-	22/27	-	2.4±3.2	20.2±4.5	22.4±6.4	40.4±7.4	83.0±14.5
CN-Chengdu	100	127	40.2±11.8	38.1±14.9	30/70	42/85	15.5±10.3	13.2±5.8	21.0±6.3	28.2±5.7	62.3±13.1
CN-Taibei	158	254	43.9±11.0	38.0±12.0	93/65	136/118	15.7±10.1	9.6±3.2	10.0±5.5	20.7±4.4	40.3±10.7
CN-Zhengzhou	194	59	23.2±8.6	26.5±5.5	97/97	32/27	-	22.3±5.1	23.1±6.3	44.1±7.9	89.5±15.0
CN-Beijing	130	0	21.3±4.2	-	75/55	-	-	22.4±5.0	20.9±7.2	38.8±7.0	82.1±15.1
CN-Xian	39	51	23.9±8.6	21.1±4.0	17/22	18/33	1.2±1.8	22.9±4.9	21.4±6.4	44.8±8.8	89.1±14.6
HCP-EP	52	39	21.9±3.0	25.4±4.4	15/39	14/25	-	11.7±3.9	16.0±5.6	24.9±4.5	52.7±10.1
COBRE	79	86	37.8±13.8	38.7±11.9	15/64	23/63	15.6±12.6	15.2±5.0	15.2±5.4	29.2±9.1	59.6±15.6
fBIRN	42	65	38.1±11.8	38.3±11.2	14/28	29/36	-	-	-	-	-
MCIC	109	95	33.8±11.2	32.9±12.2	26/83	30/65	11.1±10.9	-	-	-	-
NMorphCH	44	43	32.5±6.9	31.5±8.4	14/30	22/21	-	-	-	-	-
NUSDAST	123	127	33.8±12.5	32.6±13.8	42/81	62/65	-	-	-	-	-
DS000030	50	121	36.5±8.9	31.6±8.8	12/38	56/65	-	-	-	-	-
DS000115	22	18	24.2±3.8	20.7±4.8	6/16	8/10	-	-	-	-	-
DS004302	46	24	42.5±10.7	39.5±14.3	10/36	7/17	-	-	-	-	-
Total	1799	1532	29.9±11.9	31.3±11.8	762/1037	702/830	7.4±10.0	18.7±6.9	17.3±7.6	35.4±10.5	71.3±20.7

### Supplementary Table 2. Dataset-specific information.

Diagnosis		Scanner		
Cohort	measurement	Exclusion/inclusion criteria	manufacturer and	Imaging protocols
	measurement		type	
		All the subjects were Mandarin-speaking Han Chinese individuals from Shanghai metropolitan area.		
		The FES patients were identified according to DSM-IV criteria by qualified psychiatrists using all		
ON		available clinical information including a diagnostic interview of patients and their family, clinical case		GE Sigma 3.0 T MR (GE Medical Systems, Milwaukee, Wisconsin). TR =
CN-	DSM-IV	notes, and clinician's observations. All healthy subjects were assessed in accordance with DSM-IV	GE Sigma 3T	7.8 ms; TE = 3.65 ms; flip angle = 7°; matrix = 256×256; voxel size = 1×1×1
Shanghai1		criteria as being free of schizophrenia and other axis I disorders, and none had neurological		mm.
		diseases, head trauma, or substance abuse. All participants were right-handed; had no history of		
		substance abuse or suicidal ideation; and had no MRI contraindications.		
CN- Shanghai2	DSM-IV	The exclusion criteria were as follows: (1) brain trauma, substance-related disorders, major medical or neurologic disorders; (2) other mental disorders meeting DSM-IV criteria; (3) drug or alcohol abuse; (4) pregnancy, breastfeeding or other unstable clinical state including aggressive behaviour; (5) history of electroconvulsive therapy or transcranial magnetic stimulation within six months; and (6) other contraindications to MRI scanning. To eliminate potential familial effects, healthy subjects whose first- or second-degree relatives had a history of mental disorders were also excluded.	3T Siemens MR B17	A 3-Tesla MRI scanner (Siemens MR B17) was used to acquire data in the Shanghai Mental Health Centre. High-spatial-resolution T1-weighted images were collected by a magnetization-prepared rapid acquisition gradient echo (MPRAGE) sequence. The main parameters included repetition time/echo time, 2530/2.56 msec; flip angle, 7°; field of view, 256 × 256 mm2; matrix size, 256 × 256; section thickness, 1 mm (no gap); and voxel size, 1×1×1mm3.
CN- Shanghai3	DSM-IV-TR	Inpatients with schizophrenia were recruited from the Shanghai Mental Health Center (SMHC). All the patients were recruited from October 2013 to January 2015. All patients met criteria for schizophrenia or schizoaffective disorder based on the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-IVTR) as conducted by senior psychiatrists. The severity of psychotic symptoms was assessed by the Positive and Negative Syndrome Scale (PANSS). All patients had a total PANSS score of 60 or more and had not received ECT during the past six months. All health controls did not have a lifetime psychiatric disorder or family history of psychosis in their first-degree relatives. Participants were excluded if they had brain injuries, organic mental disorders, neurologic abnormalities, other serious physical illnesses, dementia, substance abuse or dependence, or contraindications to MRI.	3-T Siemens Magnetom Verio Syngo MR B17	High-resolution T1-weighted images were acquired using a 3-T Siemens Magnetom Verio Syngo MR B17 scanner. High-resolution T1-weighted images were collected with a magnetization-prepared rapid acquisition gradient echo (MPRAGE) sequence (TR = 2530 ms; TE = 2.56 ms; flip angle = 7°; inversion time = 1100 ms; FOV = 256 mm × 256 mm; matrix = 256 × 256; slice thickness = 1 mm; 224 slices; and voxel size = $1.0 \times 1.0 \times 1.0 \text{ mm}$ ).
CN-Harbin	DCM-IV SCID	Patient recruitment criterion was based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition and Structured Clinical Interview for DSM (SCID), which includes: (1) Age range between 14-45 years old; (2) Intelligence quotient (IQ)>69; (3) The first onset and no systematic antipsychotic treatment before admission; (4) Psychotic symptom assessment scale (positive and negative symptom scale score) is greater than or equal to 60; clinical overall	3.0 Tesla GE Discovery MR750	All scans were acquired on the same 3.0 Tesla GE Discovery MR750 scanner equipped with a 32-channel head coil.

		impression CGI severity is greater than or equal to 4 points; (5) Exclude other Axis I mental		
		disorders except schizophrenia, and have no DSM-5 drug or alcohol dependence within the past		
		three months. Exclusion criteria for patients included the following: (1) Sensory-motor disturbances		
		(hearing impairment, blindness), neurological disorders (brain injury, epilepsy), or other medical		
		conditions (2) claustrophobic and unable to undergo MRI scans; (3) patients with repetitive		
		transcranial magnetic stimulation or MRI Contraindications to scanning, such as those with metal		
		implants in the body; (4) suicide attempters, pregnant or breastfeeding women.		
CN- Chengdu	DSM-IV	Patients with SZ were recruited from the Clinical Hospital of Chengdu Brain Science Institute. Each patient was diagnosed based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Subjects with a history of brain injuries, substance-related disorders, major medical or neurological disorder were excluded. To exclude the potential effect of similar genetic backgrounds, the history of psychiatric disorder in a first- or second-degree relative was an additional exclusion criterion for healthy controls.	3-Tesla GE DISCOVERY MR 750	A 3-Tesla MRI scanner (GE DISCOVERY MR 750, USA) was used to collect imaging data in the University of Electronic Science and Technology of China. High-resolution T1-weighted images were acquired using a three dimensional fast spoiled gradient echo (T1-3D FSPGR) sequence. The main parameters include: TR = 6.008 ms; TE = 1.984 ms; flip angle (FA) =90°; field of view (FOV) = 25.6 cm × 25.6 cm; matrix size = 256 × 256; slice thickness = 1 mm (no gap).
		Patients and matched healthy controls were recruited from the Veteran General Hospital in Taipei.		
		Taiwan. All participants were diagnosed according to the Diagnostic and Statistical Manual of Mental		
		Disorder-IV criteria for schizophrenia, and each participant's history of medical disease, psychiatric		Siemens MAGNETOM Tim Trio 3.0T MRI Scanner (Siemens Healthcare,
		illness, and medication use was evaluated by interview and medical charts carefully. Any		Erlangen, Germany) with a 12- channel head coil, using 3-dimensional
CN-Taibei	DSM-IV	participants with the following conditions were excluded: (1) a comorbid substance-related disorder,	3T Siemens	magnetization prepared rapid gradient-echo sequence. TR: 2530 ms, TE:
CN-Taibei		(2) presence of neurobiological disorders, such as dementia, head injury, stroke, or Parkinson's		3.5 ms, TI: 1,100 ms, FoV: 256 mm, flip angle: 7 degree, 192 sagittal slices,
		disease; (3) presence of hypertension, diabetes, hyperlipidemia or coronary heart disease; (4)		voxel size = 1.0 mm3 cubic, no gap.
		severe medical illness, such as malignancy, heart failure, or renal failure; (4) presence of		
CN- Chengdu		ferromagnetic foreign bodies or implants that were anywhere in the body.		
		All patients were identified according to the Diagnosis and Statistic Manual of Mental Disorders,		
		fourth edition (DSM-IV) criteria for schizophrenia by qualified psychiatrists using all available clinical		
		information including a diagnostic interview, clinical case notes, and clinician's observations. The		
		severity of positive and negative symptoms was assessed by trained and experienced psychiatrists		CE MD750 2T MDI scoppor with stopdard quadrature boad coil TP/TE- 9 2
CN-	DSM-IV	using PANSS scoring. Individuals were excluded from the study if they were diagnosed with	GE MR750 3T	(3.2  ms  EOV - 256  y 256  mm 2) Matrix - 256 y 256 slice thickness - 1.0 mm
Zhengzhou	DOMIN	schizoaffective disorder, mood disorders, other cognitive disorders, epilepsy, had severe physical		7.52 ms, $1.03 - 2500250$ mm z, matrix 2002250, site universis - 1.0 mm,
		diseases, alcohol/drug dependence, or been treated with electroconvulsive therapy. Healthy		yaμ - omm, του contiguous sagitar sinces; flip angle = 12.
		subjects were assessed in accordance with DSM-IV criteria as being free of schizophrenia and other		
		Axis I disorder, and none had neurological diseases, head trauma, substance abuse, suicidal		
		ideation, and MRI contraindications.		

		The inclusion criteria were: (1) both in- and out-patients, (2) both genders, (3) diagnosis of		
		schizophrenia established with Structured Clinical Interview for the DSM-IV Axis I Disorder, patient		
		edition, (4) aged between 18 and 45 years, (5) onset at age $\geq$ 15 years, (6) first episode of		
CN Roiiing		schizophrenia, (7) no previous psychiatric treatment ('drug-naïve' status), and (8) ability to	Siemens Trio Trim	Main parameters: TR: 9.8 ms, TE: 3.8 ms, TI: 450 ms, FoV: 512 x 512, flip
CIN-Deijiriy	D3W-IV	understand the contents of interview and provide written informed consent.	3.0 T	angle: 13, slice thickness=1.2 mm.
		The exclusion criteria were: (1) a history or diagnosis of major medical conditions, (2) a history of		
		alcohol and / or drug abuse or dependence, and (3) contra-indication to olanzapine, aripiprazole, or		
		risperidone.		
		Inclusion criteria were the following: (1) diagnosis of schizophrenia using the Structured Clinical		High-resolution T1-weighted MRI was acquired using a GE Discovery
		Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID-IV), (2)		MR750 3.0 T scanner located in the Department of Radiology, and all
		patients were taking stable doses of antipsychotic medication for at least 8 weeks before the study;	GE Discovery MR750	subjects underwent T2WI scans to rule out organic diseases. The scanning
CIN-XIAN	DSIM-IV, DSIM-V	(3) no history of significant head trauma or neurological disorders and no focal brain lesions by T1-	3.0 T	parameters were repetition time 8.2 ms, echo time 3.2 ms, flip angle 12°,
		or T2-weighted MRI; (4) no alcohol or drug abuse; and (5) patient has no recent aggression or other		field of view 256 × 256 mm, matrix 256 × 256, slice thickness 1 mm, and
		forms of behavioral dysfunction.		sagittal slices 196.
HCP-EP	DSM-V	Available at https://www.humanconnectome.org/s	tudy/human-connectome-	project-for-early-psychosis
		All participants were in the 18-65 age range and had a diagnosis of schizophrenia. Healthy		T1-weighted images were acquired with a 5-echo multi-echo MPRAGE
		individuals were included if they did not have a personal or family history of psychiatric disorders.		sequence [TE (echo times) = 1.64, 3.5, 5.36, 7.22, 9.08 ms, TR (repetition
COBRE	SCID DSM-IV AXIS	History of neurological disorder, history of mental retardation, history of severe head trauma with	3T Siemens TIM Trio	time) = 2.53 s, TI (inversion time) = 1.2 s, 7° flip angle, number of excitations
	I Disolders	more than 5 minutes loss of consciousness, history of substance abuse or dependence within the		(NEX) = 1, slice thickness = 1 mm, FOV (field of view) = 256 mm, resolution
		last 12 months and MRI contraindications.		= 256x256].
				High-resolution structural imaging scans were acquired on six 3T Siemens
		All subjects diagnosed with schizenbrania ware clinically stable outpatients where entipsychotic		Tim® Trio System and one 3T General Electric Discovery MR750 scanner.
		an subjects diagnosed with schizophrienia were clinically stable outpatients whose antipsycholic		MP-RAGE scan parameters for the Siemens scanner were: scan
		volunteere with a bistory of maior medical illages, drug dependence in the last five years (except for		plane=sagittal, TR/TE/TI=2300/2.94/1100ms, GRAPPA acceleration
FRIDN		volunteers with a history of major medical liness, drug dependence in the last rive years (exception	3T Siemens Tim Trio;	factor=2, flip angle=9°, resolution=256x256x160, FOV=220mm2, voxel
IDIKIN		with aphizaphrania who had significant tardivo dvokinacio and healthy volunteers with a surrent or	3T GE	size=0.86x0.86x1.2mm, and NEX=1. IR-SPGR scan parameters for the
		with schizophiering who had significant tardive dyskinesia and reality volunteers with a current of		General Electric scanner were: scan plane=sagittal,
		Axis L psychotic disorder diagnosis were also excluded		TR/TE/TI=5.95/1.99/450ms, ASSET acceleration factor=2, a flip angle=12°,
		Ansi psycholic disorder diagnosis were also excluded.		resolution=256x256x166, FOV=220mm2, voxel size=0.86x0.86x1.2mm, and
				NEX=1. All scans covered the entire brain.
	SCID DSM-IV	All subjects were between the ages of 18 and 60 and spoke English as their native language. To be	1.5 3T Siemens and	T1 scans: TR = 2530 ms for 3 T, TR = 12 ms for 1.5 T; TE = 3.79 ms for 3 T,
MCIC	(SCID-NP for	included in the schizophrenia cohort, patients had to meet diagnostic criteria for schizophrenia,	GE	TE = 4.76 ms for 1.5 T; FA = 7 for 3 T, FA = 20 for 1.5 T; TI = 1100 for 3 T;
	controls) or CASH	schizoaffective disorder, or schizophreniform disorder. Concerted effort was made to recruit patients	52	Bandwidth = 181 for 3 T, Bandwidth = 110 for 1.5 T; $0.625 \times 0.625$ mm voxel

	were used to	early in the course of their illness and especially those who were antipsychotic drug naïve. The		size; slice thickness 1.5 mm; FOV 256×256×128 cm matrix; FOV = 16 cm
	diagnose primary	healthy control subjects with no current or past history of psychiatric illness including substance		(could be increased to 18 cm when needed for full brain coverage).
	and co-morbid	abuse or dependence were matched within site to the patient cohort for age, sex, and parental		
	psychiatric	education. Control subjects who had not been diagnosed with any psychiatric disorders, but had		
	disorders in	been medicated with antidepressants, anti-anxiety medication or medication for sleep disturbance		
	controls and	were included in the study provided that the duration of their medication did not exceed 2 months of		
	patients	lifetime use and no medication was used within the 6 months preceding the baseline MRI scan.		
		Control subjects who met criteria for current or past history of substance abuse or dependence were		
		excluded from the study. Patients, however, were not excluded from the study unless criteria were		
		met for current (i.e., within the past month) abuse or dependence (except for 6 patients who were		
		found to meet criteria for current abuse after the study data was collected). Both patients and		
		controls were excluded if they had (1) an IQ less than 70 based on a standardized IQ test, (2) history		
		of a head injury resulting in prolonged loss of consciousness, neurosurgical procedure, neurological		
		disease, history of skull fracture, severe or disabling medical conditions, or (3) a contraindication for		
		MRI scanning such as pregnancy, metal in body or head including implanted pacemaker, medication		
		pump, vagal stimulator, deep brain stimulator, implanted TENS unit, or ventriculo-peritoneal shunt		
This is a longitudina		study examining the clinical, cognitive and neuroimaging (MRI) data from schizophrenia and control		
This sub	subjects at baseline a	and after two years. The study was conducted at Northwestern University. Neuroimaging data	<u>эт</u>	MPRAGE:voxel size =1x1x1.6 mm3; Matrix size 256x256; TR=3.15ms;
NINOIPIICH	includes T1, T2, DTI,	resting-state fMRI and n-back task fMRI. More details are provide at	31	TE=20ms; Flip ange=8.0
	http://www.schizconn	ect.org/documentation		
	The Northwestern Ur	iversity Schizophrenia Data and Software Tool (NUSDAST) is a repository of schizophrenia		
	neuroimaging data co	ollected from over 450 individuals with schizophrenia, healthy controls and their respective siblings,	Siemens 1.5 T Vision	3D MPRAGE (TR = 9.7 ms, TE = 4 ms, flip = 10°, ACQ = 1, 256 × 256
NUSDASI	most with 2-year long	itudinal follow-up. More details are provided at: Wang L, Kogan A, Cobia D, et al. Northwestern	scanner	matrix, 1 x I mm in-plane resolution, 128 slices, slice thickness 1.25 mm)
	University schizophre	enia data and software tool (NUSDAST). Frontiers in neuroinformatics, 2013, 7: 25.		
		For both healthy and patient groups, participants were men or women ages 21–50 years; NIH		
		racial/ethnic category either White, not Hispanic or Latino; or Hispanic or Latino, of any racial		
		group; primary language either English or Spanish; completed at least 8 years of formal		
		education; no significant medical illness; adequate cooperation to complete assessments;	Siamana Tria (2	A T1-weighted high-resolution anatomical scan (MPRAGE) were collected
DS000030	DSM-IV	visual acuity 20/60 or better; and urinalysis negative for drugs of abuse (Cocaine;	Stemens Tho (2	with the following parameter: slice thickness = 1mm, 176 slices, TR=1.9s,
		Methamphetamine; Morphine; THC; and Benzodiazepines).	imaging Siles)	TE=2.26ms, matrix=256 x 256, FOV=250mm.
		Participants in the healthy group were excluded if they had lifetime diagnoses of Schizophrenia or		
)S000030		Other Psychotic Disorder, Bipolar I or II Disorder, or Substance Abuse or Dependence (not counting		
		caffeine or nicotine); or current Major Depressive Disorder; suicidality; Anxiety Disorder		

		(Obsessive Compulsive Disorder, Panic Disorder, Generalized Anxiety Disorder, Post-Traumatic			
		Stress Disorder), Attention Deficit Hyperactivity Disorder (ADHD). ADHD criteria were assessed			
		using Adult ADHD Interview; healthy participants were screened for sub-threshold ADHD, defined			
		as 4 or more ADHD inattentive or hyperactive/impulsive symptoms in either childhood and			
		adulthood; in addition, they could not have had medication treatment for ADHD within the prior 12			
		months. Each of the patient groups (Schizophrenia, Bipolar Disorder, and ADHD) excluded anyone			
		with one of these other diagnoses; stable medications were permitted for the patients. For MRI			
		studies we excluded participants who were left handed, who believed they might be pregnant, or had			
		other contraindications to scanning (e.g., claustrophobia, metal in body, body too large to fit in			
		scanner).			
		More details are provided at https://www.nature.com/articles/sdata2016110			
		All subjects were diagnosed on the basis of a consensus between a research psychiatrist who			
DS000115 DSM-IV		conducted a semi-structured interview and a trained research assistant who used the Structured			
		Clinical Interview for DSM-IV Axis I Disorders. Participants were excluded if they: (a) met DSM-IV			
		criteria for substance dependence or severe/moderate abuse during the prior 6 months; (b) had a			
	DSM-IV	clinically unstable or severe medical disorder; (c) had a history of head injury with documented	3T Siemens Trio	11 structural image was acquired using a sagittal MP-RAGE 3D sequence	
		neurological sequelae or loss of consciousness; or (d) met DSM-IV criteria for mental retardation.		$(1R = 2400 \text{ ms}, 1E = 3.16 \text{ ms}, 1 \text{ mp} = 8^\circ; \text{ voxel size} = 1 \text{ mm} \times 1 \text{ mm} \times 1 \text{ mm}).$	
		The individuals with schizophrenia were all outpatients, and were stabilized on antipsychotic			
		medication for at least 2 weeks. Controls were required to have no lifetime history of Axis I psychotic			
		or mood disorders and no first-degree relatives with a psychotic disorder.			
		Patients meeting DSM-5 criteria for schizophrenia were initially recruited from four psychiatric			
		hospitals in Barcelona. Diagnoses were made using the Structured Clinical Interview for DSM			
		Disorders (SCID). Patients were excluded if they (a) were younger than 18 or older than 65, (b)			
		had a history of brain trauma or neurological disease or (c) had shown alcohol/substance			
		abuse/dependence within 12 months prior to participation. Social use of alcohol was permitted, as		Images were acquired with a 31 Philips Ingenia scanner (Philips Medical	
D0004000	DOMN	was non-habitual use of cannabis. Electroconvulsive therapy in the past 6 months was also an	3T Philips Ingenia	Systems, Best, The Netherlands). High-resolution anatomical volume with	
DS004302	DSM-V	exclusion criterion. All participants were right-handed and were taking antipsychotic medication.	scanner	(TD = 0.00 TE = 1.00 EI' = 1 = 0.00 EI'	
		Healthy controls met the same exclusion criteria as the patients, and they were also interviewed		(1R = 9.90ms; 1E = 4.60ms; 11p angle = 8"; voxel size = 1 x 1mm; silce	
		using the SCID to exclude current and past psychiatric disorders. They were questioned and		thickness = 1mm; slice number = $180$ ; FOV = $240$ mm).	
		excluded if they reported a history of treatment with psychotropic medication beyond non-habitual			
		use of night sedation. Controls were also excluded if they reported a history of major psychiatric			
		disorder in a first-degree relative.			

Sup	plementary	<sup>7</sup> Table S3. Mean	difference in	regional grav	v matter volume	measures
					,	

		Effect size		t test	
Classification	Region	(Cohend's d)	t value	p value	FDR(p<0.05)
Thalamus	L_thalamus	0.29	-8.29	1.11E-16	*
Basal Ganglia	L_caudate	-0.05	1.65	9.93E-02	
Basal Ganglia	L_putamen	-0.04	0.84	4.00E-01	
Basal Ganglia	L_pallidum	-0.13	4.10	4.31E-05	*
Hippcampus	L_hippocampus	0.38	-12.00	0.00E+00	*
Amygdala	L_amygdala	0.25	-7.55	5.55E-14	*
Basal Ganglia	L_accumbens	0.21	-6.10	1.20E-09	*
Thalamus	R_thalamus	0.32	-9.17	0.00E+00	*
Basal Ganglia	R_caudate	-0.07	2.18	2.96E-02	
Basal Ganglia	R_putamen	-0.06	1.55	1.21E-01	
Basal Ganglia	R_pallidum	-0.16	4.86	1.21E-06	*
Hippcampus	R_hippocampus	0.35	-10.69	0.00E+00	*
Amygdala	R_amygdala	0.16	-5.16	2.68E-07	*
Basal Ganglia	R_accumbens	0.24	-7.18	8.50E-13	*
Temporal	L_bankssts	0.14	-3.74	1.86E-04	*
Cingulate	L_caudalanteriorcingulate	0.11	-3.01	2.62E-03	*
Frontal	L_caudalmiddlefrontal	0.15	-4.62	4.06E-06	*
Occipital	L_cuneus	0.12	-3.34	8.38E-04	*
Temporal	L_entorhinal	0.09	-2.22	2.67E-02	*
Temporal	L_fusiform	0.26	-7.80	8.55E-15	*
Parietal	L_inferiorparietal	0.21	-6.26	4.37E-10	*
Temporal	L_inferiortemporal	0.24	-7.10	1.54E-12	*
Cingulate	L_isthmuscingulate	0.11	-3.39	7.16E-04	*
Occipital	L_lateraloccipital	0.25	-7.01	2.89E-12	*
Frontal	L_lateralorbitofrontal	0.24	-7.16	9.73E-13	*
Occipital	L_lingual	0.19	-5.52	3.65E-08	*
Frontal	L_medialorbitofrontal	0.12	-3.75	1.82E-04	*
Temporal	L_middletemporal	0.23	-6.72	2.09E-11	*
Temporal	L_parahippocampal	0.16	-4.75	2.14E-06	*
Somatosensory	L_paracentral	0.17	-4.84	1.37E-06	*
Frontal	L_parsopercularis	0.18	-5.41	6.74E-08	*
Frontal	L_parsorbitalis	0.17	-5.22	1.87E-07	*
Frontal	L_parstriangularis	0.16	-4.74	2.27E-06	*
Occipital	L_pericalcarine	0.04	-0.74	4.58E-01	
Somatosensory	L_postcentral	0.27	-7.95	2.55E-15	*
Cingulate	L_posteriorcingulate	0.18	-5.79	7.70E-09	*
Somatosensory	L_precentral	0.30	-8.74	0.00E+00	*
Parietal	L_precuneus	0.18	-5.41	6.67E-08	*
Cingulate	L_rostralanteriorcingulate	0.16	-4.33	1.52E-05	*
Frontal	L_rostralmiddlefrontal	0.19	-5.83	6.10E-09	*
Frontal	L_superiorfrontal	0.30	-8.75	0.00E+00	*
Parietal	L_superiorparietal	0.15	-4.41	1.07E-05	*
Temporal	L_superiortemporal	0.28	-8.23	2.22E-16	*
Parietal	L_supramarginal	0.25	-7.10	1.56E-12	*
Frontal	L_frontalpole	0.08	-2.61	9.10E-03	*
Temporal	L_temporalpole	0.03	-0.76	4.45E-01	

Temporal	L_transversetemporal	0.17	-5.20	2.10E-07	*
Insula	L_insula	0.29	-8.70	0.00E+00	*
Temporal	R_bankssts	0.18	-5.31	1.16E-07	*
Cingulate	R_caudalanteriorcingulate	0.11	-3.09	2.05E-03	*
Frontal	R_caudalmiddlefrontal	0.15	-4.30	1.78E-05	*
Occipital	R_cuneus	0.16	-4.57	5.04E-06	*
Temporal	R_entorhinal	0.07	-1.95	5.18E-02	
Temporal	R_fusiform	0.28	-8.65	0.00E+00	*
Parietal	R_inferiorparietal	0.24	-7.06	2.05E-12	*
Temporal	R_inferiortemporal	0.25	-7.35	2.57E-13	*
Cingulate	R_isthmuscingulate	0.14	-4.65	3.38E-06	*
Occipital	R_lateraloccipital	0.24	-6.95	4.30E-12	*
Frontal	R_lateralorbitofrontal	0.20	-5.69	1.38E-08	*
Occipital	R_lingual	0.17	-5.02	5.39E-07	*
Frontal	R_medialorbitofrontal	0.25	-7.21	7.13E-13	*
Temporal	R_middletemporal	0.24	-7.18	8.78E-13	*
Temporal	R_parahippocampal	0.19	-5.76	8.92E-09	*
Somatosensory	R_paracentral	0.23	-6.64	3.62E-11	*
Frontal	R_parsopercularis	0.17	-5.17	2.50E-07	*
Frontal	R_parsorbitalis	0.14	-4.08	4.67E-05	*
Frontal	R_parstriangularis	0.13	-3.97	7.41E-05	*
Occipital	R_pericalcarine	0.02	-0.43	6.69E-01	
Somatosensory	R_postcentral	0.22	-6.36	2.26E-10	*
Cingulate	R_posteriorcingulate	0.24	-7.35	2.45E-13	*
Somatosensory	R_precentral	0.23	-6.87	7.45E-12	*
Parietal	R_precuneus	0.20	-6.01	2.05E-09	*
Cingulate	R_rostralanteriorcingulate	0.18	-4.90	1.00E-06	*
Frontal	R_rostralmiddlefrontal	0.15	-4.49	7.30E-06	*
Frontal	R_superiorfrontal	0.26	-7.62	3.31E-14	*
Parietal	R_superiorparietal	0.18	-5.20	2.10E-07	*
Temporal	R_superiortemporal	0.26	-7.88	4.55E-15	*
Parietal	R_supramarginal	0.20	-6.01	2.10E-09	*
Frontal	R_frontalpole	0.12	-3.83	1.30E-04	*
Temporal	R_temporalpole	0.02	-0.73	4.67E-01	
Temporal	R_transversetemporal	0.24	-7.16	9.77E-13	*
Insula	R_insula	0.27	-8.05	1.11E-15	*

		All	patients group	)	First-epis	First-episode drug-naive group			Chronic medicated group		
Classification	Region			FDR				FDR L OV P		FDR	
		InCVR	p value	(p<0.05)	InCVR	p values	(p<0.05)	InCVR	p values	(p<0.05)	
Thalamus	L_thalamus	0.167	0.00E+00	*	0.285	0.00E+00	*	0.158	0.00E+00	*	
Basal Ganglia	L_caudate	0.135	0.00E+00	*	0.179	0.00E+00	*	0.214	0.00E+00	*	
Basal Ganglia	L_putamen	0.089	2.00E-03	*	0.226	0.00E+00	*	0.088	3.20E-02		
Basal Ganglia	L_pallidum	0.051	8.40E-02		-0.006	8.60E-01		0.091	1.50E-02	*	
Hippcampus	L_hippocampus	0.145	0.00E+00	*	0.176	0.00E+00	*	0.238	0.00E+00	*	
Amygdala	L_amygdala	0.065	2.50E-02		0.016	6.81E-01		0.070	5.50E-02		
Basal Ganglia	L_accumbens	0.128	0.00E+00	*	0.162	0.00E+00	*	0.113	0.00E+00	*	
Thalamus	R_thalamus	0.165	0.00E+00	*	0.289	0.00E+00	*	0.117	1.00E-03	*	
Basal Ganglia	R_caudate	0.143	0.00E+00	*	0.201	0.00E+00	*	0.205	0.00E+00	*	
Basal Ganglia	R_putamen	0.085	9.00E-03	*	0.201	0.00E+00	*	0.115	4.00E-03	*	
Basal Ganglia	R_pallidum	0.070	1.70E-02	*	0.074	4.50E-02		0.139	1.00E-03	*	
Hippcampus	R_hippocampus	0.127	1.00E-03	*	0.091	1.40E-02	*	0.233	0.00E+00	*	
Amygdala	R_amygdala	0.067	2.50E-02		0.071	9.70E-02		0.101	1.00E-02	*	
Basal Ganglia	R_accumbens	0.084	2.00E-03	*	0.065	5.10E-02		0.150	0.00E+00	*	
Temporal	L_bankssts	0.033	2.34E-01		0.107	3.00E-03	*	0.009	8.14E-01		
Cingulate	L_caudalanteriorcingulate	0.017	5.57E-01		0.086	1.40E-02	*	-0.066	5.30E-02		
Frontal	L_caudalmiddlefrontal	0.080	4.00E-03	*	0.218	0.00E+00	*	0.073	3.00E-02		
Occipital	L_cuneus	-0.002	9.24E-01		-0.035	2.81E-01		-0.104	1.00E-03	*	
Temporal	L_entorhinal	0.071	3.90E-02		0.149	0.00E+00	*	-0.060	1.26E-01		
Temporal	L_fusiform	0.125	0.00E+00	*	0.179	0.00E+00	*	0.106	3.00E-03	*	
Parietal	L_inferiorparietal	0.061	1.70E-02	*	0.158	0.00E+00	*	0.028	4.18E-01		
Temporal	L_inferiortemporal	0.089	1.00E-03	*	0.132	0.00E+00	*	0.110	0.00E+00	*	
Cingulate	L_isthmuscingulate	0.044	9.90E-02		0.126	0.00E+00	*	0.098	6.00E-03	*	
Occipital	L_lateraloccipital	0.060	2.60E-02		0.154	0.00E+00	*	-0.003	9.14E-01		
Frontal	L_lateralorbitofrontal	0.122	0.00E+00	*	0.245	0.00E+00	*	0.155	0.00E+00	*	
Occipital	L_lingual	0.057	2.20E-02	*	0.111	2.00E-03	*	-0.003	9.31E-01		
Frontal	L_medialorbitofrontal	0.068	1.40E-02	*	0.136	0.00E+00	*	0.077	4.30E-02		
Temporal	L_middletemporal	0.110	0.00E+00	*	0.163	0.00E+00	*	0.150	0.00E+00	*	
Temporal	L_parahippocampal	0.034	2.74E-01		0.071	4.40E-02		-0.100	4.00E-03	*	

Supplementary Table S4. Variability difference in regional gray matter volume measures

Somatosensory	L_paracentral	0.031	2.93E-01		0.114	6.00E-03	*	-0.043	3.30E-01	
Frontal	L_parsopercularis	0.017	6.30E-01		0.158	0.00E+00	*	-0.060	2.05E-01	
Frontal	L_parsorbitalis	0.123	0.00E+00	*	0.269	0.00E+00	*	0.013	6.98E-01	
Frontal	L_parstriangularis	0.030	2.72E-01		0.187	0.00E+00	*	-0.047	1.75E-01	
Occipital	L_pericalcarine	-0.011	6.47E-01		0.069	1.80E-02	*	-0.154	0.00E+00	*
Somatosensory	L_postcentral	0.057	1.42E-01		0.144	1.00E-03	*	0.017	7.75E-01	
Cingulate	L_posteriorcingulate	0.057	5.30E-02		0.134	0.00E+00	*	0.080	4.40E-02	
Somatosensory	L_precentral	0.072	4.10E-02		0.249	0.00E+00	*	0.072	9.20E-02	
Parietal	L_precuneus	0.077	7.00E-03	*	0.175	0.00E+00	*	0.077	5.20E-02	
Cingulate	L_rostralanteriorcingulate	0.040	1.30E-01		0.094	3.00E-03	*	0.004	9.31E-01	
Frontal	L_rostralmiddlefrontal	0.086	1.20E-02	*	0.200	0.00E+00	*	0.072	1.38E-01	
Frontal	L_superiorfrontal	0.127	0.00E+00	*	0.219	0.00E+00	*	0.138	0.00E+00	*
Parietal	L_superiorparietal	0.076	7.00E-03	*	0.135	1.00E-03	*	0.067	9.70E-02	
Temporal	L_superiortemporal	0.097	0.00E+00	*	0.174	0.00E+00	*	0.097	5.00E-03	*
Parietal	L_supramarginal	0.023	4.13E-01		0.094	1.00E-02	*	0.044	2.23E-01	
Frontal	L_frontalpole	0.074	4.10E-02		0.212	0.00E+00	*	-0.034	4.68E-01	
Temporal	L_temporalpole	0.038	1.94E-01		0.080	3.90E-02	*	-0.042	2.80E-01	
Temporal	L_transversetemporal	0.055	4.30E-02		0.104	2.00E-03	*	0.082	1.00E-02	*
Insula	L_insula	0.029	3.23E-01		0.134	1.00E-03	*	0.079	3.50E-02	
Temporal	R_bankssts	0.128	0.00E+00	*	0.239	0.00E+00	*	0.031	3.84E-01	
Cingulate	R_caudalanteriorcingulate	0.061	3.00E-02		0.199	0.00E+00	*	0.024	5.09E-01	
Frontal	R_caudalmiddlefrontal	0.022	4.67E-01		0.084	2.20E-02	*	-0.004	9.02E-01	
Occipital	R_cuneus	-0.008	7.95E-01		-0.043	3.07E-01		-0.043	2.84E-01	
Temporal	R_entorhinal	0.026	4.26E-01		0.110	1.60E-02	*	-0.029	4.60E-01	
Temporal	R_fusiform	0.080	1.00E-03	*	0.130	0.00E+00	*	0.030	4.15E-01	
Parietal	R_inferiorparietal	0.062	1.60E-02	*	0.190	0.00E+00	*	0.016	6.46E-01	
Temporal	R_inferiortemporal	0.083	7.00E-03	*	0.144	0.00E+00	*	0.039	2.65E-01	
Cingulate	R_isthmuscingulate	0.080	5.00E-03	*	0.179	0.00E+00	*	0.083	1.90E-02	
Occipital	R_lateraloccipital	0.077	8.00E-03	*	0.181	0.00E+00	*	0.040	2.61E-01	
Frontal	R_lateralorbitofrontal	0.131	1.00E-03	*	0.275	0.00E+00	*	0.087	3.40E-02	
Occipital	R_lingual	0.060	2.80E-02		0.084	6.00E-03	*	-0.004	9.15E-01	
Frontal	R_medialorbitofrontal	0.115	0.00E+00	*	0.216	0.00E+00	*	0.137	0.00E+00	*
Temporal	R_middletemporal	0.087	1.00E-03	*	0.125	0.00E+00	*	0.128	2.00E-03	*

Temporal	R_parahippocampal	0.069	9.00E-03	*	0.125	0.00E+00	*	-0.002	9.53E-01	
Somatosensory	R_paracentral	0.006	8.42E-01		0.050	1.38E-01		-0.047	2.31E-01	
Frontal	R_parsopercularis	0.103	1.00E-03	*	0.252	0.00E+00	*	-0.024	5.16E-01	
Frontal	R_parsorbitalis	0.122	0.00E+00	*	0.228	0.00E+00	*	0.007	8.31E-01	
Frontal	R_parstriangularis	0.099	0.00E+00	*	0.162	0.00E+00	*	-0.041	3.02E-01	
Occipital	R_pericalcarine	0.014	5.68E-01		0.077	1.60E-02	*	-0.106	0.00E+00	*
Somatosensory	R_postcentral	0.079	8.00E-03	*	0.136	1.00E-03	*	0.061	1.02E-01	
Cingulate	R_posteriorcingulate	0.123	0.00E+00	*	0.276	0.00E+00	*	0.115	2.00E-03	*
Somatosensory	R_precentral	0.155	0.00E+00	*	0.220	0.00E+00	*	0.137	2.00E-03	*
Parietal	R_precuneus	0.140	0.00E+00	*	0.259	0.00E+00	*	0.142	0.00E+00	*
Cingulate	R_rostralanteriorcingulate	0.125	0.00E+00	*	0.228	0.00E+00	*	0.068	5.90E-02	
Frontal	R_rostralmiddlefrontal	0.087	1.30E-02	*	0.191	0.00E+00	*	0.044	3.36E-01	
Frontal	R_superiorfrontal	0.122	0.00E+00	*	0.155	0.00E+00	*	0.101	8.00E-03	*
Parietal	R_superiorparietal	0.116	0.00E+00	*	0.170	0.00E+00	*	0.131	0.00E+00	*
Temporal	R_superiortemporal	0.178	0.00E+00	*	0.301	0.00E+00	*	0.153	0.00E+00	*
Parietal	R_supramarginal	0.126	0.00E+00	*	0.240	0.00E+00	*	0.077	2.60E-02	
Frontal	R_frontalpole	0.069	1.40E-02	*	0.140	0.00E+00	*	0.044	2.60E-01	
Temporal	R_temporalpole	0.022	4.51E-01		0.105	6.00E-03	*	-0.053	1.79E-01	
Temporal	R_transversetemporal	0.070	1.00E-02	*	0.180	0.00E+00	*	0.031	3.92E-01	
Insula	R_insula	0.062	3.70E-02		0.159	0.00E+00	*	0.083	3.50E-02	

Classification Region			All patient	s group	First-e	pisode dru	g-naive group	Chronic medicated group			
Classification	Region	PD-	PD+	(PD-)&(PD+)	PD-	PD+	(PD-)&(PD+)	PD-	PD+	(PD-)&(PD+)	
Thalamus	L_thalamus	26.1%	11.8%	37.8%	22.8%	17.8%	40.6%	30.4%	8.0%	38.4%	
Basal Ganglia	L_caudate	15.6%	18.0%	33.6%	16.5%	19.7%	36.2%	16.8%	18.3%	35.2%	
Basal Ganglia	L_putamen	14.2%	16.6%	30.8%	20.7%	18.6%	39.3%	14.1%	14.6%	28.6%	
Basal Ganglia	L_pallidum	11.2%	17.0%	28.1%	11.1%	13.0%	24.1%	10.1%	16.6%	26.6%	
Hippcampus	L_hippocampus	21.9%	7.3%	29.2%	22.0%	10.0%	32.0%	29.6%	6.3%	35.9%	
Amygdala	L_amygdala	19.5%	9.8%	29.3%	20.7%	7.7%	28.5%	22.1%	8.0%	30.2%	
Basal Ganglia	L_accumbens	21.6%	12.7%	34.3%	21.1%	12.8%	33.9%	23.6%	9.3%	32.9%	
Thalamus	R_thalamus	27.0%	12.3%	39.3%	27.6%	16.3%	43.9%	31.2%	7.5%	38.7%	
Basal Ganglia	R_caudate	14.9%	18.8%	33.6%	16.1%	18.8%	34.9%	16.3%	18.3%	34.7%	
Basal Ganglia	R_putamen	12.9%	16.5%	29.5%	18.6%	17.4%	36.0%	13.8%	13.6%	27.4%	
Basal Ganglia	R_pallidum	11.9%	19.3%	31.3%	12.8%	18.2%	31.0%	11.6%	20.9%	32.4%	
Hippcampus	R_hippocampus	23.0%	9.5%	32.6%	20.1%	10.9%	31.0%	32.2%	7.0%	39.2%	
Amygdala	R_amygdala	19.1%	11.6%	30.7%	19.0%	11.9%	31.0%	27.1%	9.3%	36.4%	
Basal Ganglia	R_accumbens	19.6%	10.5%	30.1%	20.3%	10.3%	30.5%	24.1%	8.0%	32.2%	
Temporal	L_bankssts	19.3%	12.8%	32.1%	19.7%	17.8%	37.4%	21.6%	11.8%	33.4%	
Cingulate	L_caudalanteriorcingulate	16.7%	13.1%	29.8%	16.9%	17.2%	34.1%	15.3%	10.6%	25.9%	
Frontal	L_caudalmiddlefrontal	20.7%	12.0%	32.7%	20.5%	16.9%	37.4%	23.4%	11.1%	34.4%	
Occipital	L_cuneus	17.1%	12.1%	29.1%	16.3%	12.8%	29.1%	15.3%	8.3%	23.6%	
Temporal	L_entorhinal	14.3%	11.7%	25.9%	15.1%	13.4%	28.5%	13.8%	7.8%	21.6%	
Temporal	L_fusiform	24.6%	12.6%	37.2%	24.3%	15.5%	39.7%	25.1%	11.1%	36.2%	
Parietal	L_inferiorparietal	21.0%	12.3%	33.3%	21.3%	18.2%	39.5%	21.4%	8.0%	29.4%	
Temporal	L_inferiortemporal	22.5%	12.2%	34.7%	20.9%	14.9%	35.8%	26.1%	11.1%	37.2%	
Cingulate	L_isthmuscingulate	15.2%	11.8%	27.0%	18.6%	15.1%	33.7%	16.6%	11.8%	28.4%	
Occipital	L_lateraloccipital	22.2%	10.8%	32.9%	21.8%	13.2%	34.9%	22.1%	7.0%	29.1%	
Frontal	L_lateralorbitofrontal	22.1%	11.9%	34.0%	22.2%	16.5%	38.7%	27.4%	10.1%	37.4%	
Occipital	L_lingual	19.9%	11.0%	31.0%	18.4%	14.0%	32.4%	20.9%	7.5%	28.4%	
Frontal	L_medialorbitofrontal	18.7%	13.4%	32.1%	20.1%	16.5%	36.6%	20.4%	11.3%	31.7%	
Temporal	L_middletemporal	23.1%	12.9%	36.0%	24.3%	18.6%	42.9%	25.6%	11.3%	36.9%	
Temporal	L_parahippocampal	8.4%	6.3%	14.7%	8.2%	8.6%	16.7%	7.5%	3.5%	11.1%	

### Supplementary Table S5. Proportion of patients with greater deviation in regional gray matter volume measures

Somatosensory	L_paracentral	19.0%	12.3%	31.3%	18.0%	14.4%	32.4%	18.8%	10.1%	28.9%
Frontal	L_parsopercularis	17.9%	10.8%	28.7%	21.3%	15.7%	37.0%	15.8%	7.8%	23.6%
Frontal	L_parsorbitalis	20.6%	13.7%	34.3%	22.0%	20.5%	42.5%	22.6%	8.8%	31.4%
Frontal	L_parstriangularis	19.6%	12.9%	32.5%	22.0%	21.1%	43.1%	17.3%	9.5%	26.9%
Occipital	L_pericalcarine	16.0%	14.7%	30.7%	15.1%	17.4%	32.4%	12.8%	11.1%	23.9%
Somatosensory	L_postcentral	22.7%	9.8%	32.5%	22.8%	13.4%	36.2%	24.1%	8.5%	32.7%
Cingulate	L_posteriorcingulate	20.8%	12.1%	32.9%	19.9%	16.1%	36.0%	23.1%	13.1%	36.2%
Somatosensory	L_precentral	21.8%	9.2%	31.0%	22.0%	14.0%	36.0%	24.6%	8.0%	32.7%
Parietal	L_precuneus	19.5%	11.8%	31.3%	20.3%	15.9%	36.2%	21.1%	9.8%	30.9%
Cingulate	L_rostralanteriorcingulate	17.0%	11.8%	28.8%	18.4%	14.9%	33.3%	14.3%	9.8%	24.1%
Frontal	L_rostralmiddlefrontal	19.1%	10.9%	30.0%	18.2%	16.7%	34.9%	22.4%	8.0%	30.4%
Frontal	L_superiorfrontal	24.6%	10.8%	35.4%	20.5%	15.3%	35.8%	29.1%	7.0%	36.2%
Parietal	L_superiorparietal	17.7%	12.4%	30.1%	17.8%	15.7%	33.5%	18.3%	9.5%	27.9%
Temporal	L_superiortemporal	24.0%	10.4%	34.4%	22.2%	14.4%	36.6%	26.1%	8.3%	34.4%
Parietal	L_supramarginal	21.0%	9.5%	30.5%	19.9%	12.3%	32.2%	23.4%	7.8%	31.2%
Frontal	L_frontalpole	17.2%	13.4%	30.6%	17.8%	17.4%	35.1%	19.3%	8.0%	27.4%
Temporal	L_temporalpole	14.5%	13.2%	27.7%	13.6%	17.8%	31.4%	14.8%	9.3%	24.1%
Temporal	L_transversetemporal	21.7%	12.8%	34.5%	22.0%	15.5%	37.4%	23.6%	12.6%	36.2%
Insula	L_insula	14.9%	5.8%	20.7%	16.3%	8.6%	24.9%	16.1%	5.5%	21.6%
Temporal	R_bankssts	20.8%	12.8%	33.6%	19.9%	18.8%	38.7%	19.8%	10.3%	30.2%
Cingulate	R_caudalanteriorcingulate	18.5%	14.2%	32.7%	22.6%	17.6%	40.2%	20.6%	11.6%	32.2%
Frontal	R_caudalmiddlefrontal	18.4%	10.6%	29.0%	17.2%	16.5%	33.7%	17.8%	8.5%	26.4%
Occipital	R_cuneus	16.7%	11.0%	27.7%	14.9%	11.5%	26.4%	16.1%	10.1%	26.1%
Temporal	R_entorhinal	14.4%	13.3%	27.7%	15.7%	14.2%	29.9%	15.6%	11.8%	27.4%
Temporal	R_fusiform	22.9%	11.4%	34.3%	21.3%	13.6%	34.9%	23.9%	8.0%	31.9%
Parietal	R_inferiorparietal	22.2%	10.7%	32.9%	22.4%	16.9%	39.3%	23.4%	7.5%	30.9%
Temporal	R_inferiortemporal	22.2%	11.3%	33.5%	20.5%	16.3%	36.8%	24.4%	7.3%	31.7%
Cingulate	R_isthmuscingulate	19.1%	11.2%	30.4%	20.7%	14.9%	35.6%	20.9%	10.3%	31.2%
Occipital	R_lateraloccipital	21.7%	12.2%	33.9%	24.5%	14.9%	39.3%	23.9%	8.5%	32.4%
Frontal	R_lateralorbitofrontal	21.0%	13.1%	34.1%	20.9%	19.9%	40.8%	23.9%	8.5%	32.4%
Occipital	R_lingual	19.3%	11.8%	31.1%	19.2%	12.8%	32.0%	19.3%	8.8%	28.1%
Frontal	R_medialorbitofrontal	19.4%	9.5%	28.9%	19.0%	13.2%	32.2%	22.4%	6.8%	29.1%
Temporal	R_middletemporal	22.1%	11.3%	33.4%	20.5%	16.3%	36.8%	26.6%	10.1%	36.7%

Temporal	R_parahippocampal	20.5%	12.2%	32.7%	20.9%	13.2%	34.1%	21.1%	8.8%	29.9%
Somatosensory	R_paracentral	20.1%	10.7%	30.7%	18.4%	13.2%	31.6%	19.8%	7.0%	26.9%
Frontal	R_parsopercularis	19.4%	11.2%	30.6%	19.9%	15.5%	35.4%	19.8%	7.0%	26.9%
Frontal	R_parsorbitalis	21.3%	14.7%	36.0%	21.8%	20.5%	42.3%	19.8%	8.0%	27.9%
Frontal	R_parstriangularis	18.9%	12.9%	31.8%	16.9%	16.1%	33.1%	17.8%	7.8%	25.6%
Occipital	R_pericalcarine	15.2%	15.7%	31.0%	17.4%	17.2%	34.5%	10.8%	14.8%	25.6%
Somatosensory	R_postcentral	20.6%	10.8%	31.4%	19.0%	13.0%	32.0%	21.4%	8.8%	30.2%
Cingulate	R_posteriorcingulate	23.4%	11.7%	35.2%	25.9%	16.1%	42.1%	23.4%	11.1%	34.4%
Somatosensory	R_precentral	17.6%	10.7%	28.3%	17.8%	13.4%	31.2%	19.3%	10.3%	29.6%
Parietal	R_precuneus	21.4%	12.9%	34.4%	21.5%	16.5%	38.1%	21.6%	10.8%	32.4%
Cingulate	R_rostralanteriorcingulate	20.8%	12.9%	33.8%	22.4%	16.9%	39.3%	21.9%	10.6%	32.4%
Frontal	R_rostralmiddlefrontal	16.4%	10.4%	26.7%	16.7%	15.5%	32.2%	19.3%	8.3%	27.6%
Frontal	R_superiorfrontal	23.5%	11.6%	35.2%	20.3%	14.4%	34.7%	25.9%	8.3%	34.2%
Parietal	R_superiorparietal	18.4%	10.9%	29.3%	16.7%	14.4%	31.2%	21.4%	9.5%	30.9%
Temporal	R_superiortemporal	24.0%	11.6%	35.5%	22.6%	17.6%	40.2%	28.6%	10.1%	38.7%
Parietal	R_supramarginal	19.4%	11.8%	31.2%	19.5%	15.9%	35.4%	20.4%	9.8%	30.2%
Frontal	R_frontalpole	19.3%	13.2%	32.5%	19.9%	15.3%	35.1%	22.1%	9.8%	31.9%
Temporal	R_temporalpole	13.8%	14.4%	28.2%	14.9%	17.6%	32.4%	14.6%	10.8%	25.4%
Temporal	R_transversetemporal	22.3%	11.6%	33.8%	19.7%	16.9%	36.6%	25.9%	9.0%	34.9%
Insula	R_insula	13.3%	5.7%	19.1%	14.6%	7.9%	22.6%	15.6%	4.8%	20.4%

Proin mon 1	Brain man 2	Spearman	correlation test	Spatial permutation test		
Brain map i	Brain map 2	r	р	pspin		
Effect size of discovery sample	Effect size of validation sample	0.678	2.72E-12	<0.0001		
InCVR	Effect size	0.367	6.86E-04	0.0003		
InCVR	Effect size	0.489	7.42E-06	<0.0001		
InCVR	Proportion of patients in smaller volume	0.478	5.61E-06	<0.0001		
InCVR	Proportion of patients in larger volume	0.025	8.24E-01	0.5294		

#### Supplementary Table S6. Spatial correlation results

||means that test is conducted only within regions with reduction in mean volume in patients.

#### Supplementary Table S7. Correlation between brain variability map in schizophrenia and neurotransmitter map

Brain variability map	Neurotransmitter receptors and transporter density maps	Spearman correlation r value	Spearman correlation p value	Spin test p value
InCVR	MOR	0.3311	0.0024	0.0355
PD-	5HT2a	0.2986	0.0064	0.0057
PD-	DAT	-0.2421	0.0284	0.0219
PD+	5HT1a	-0.2962	0.0069	0.0356
PD+	D1	0.3372	0.0019	0.0042

#### Supplementary Table S8. Network diffusion model performances on estimating cross-sectional gray matter differences in schizophrenia.

		NDM_M	С		NDM_\$	SC	NDM_FC			
	Model Performance(r, p) Optimal seed		Optimal seed	Model Pe	rformance(r, p)	Optimal seed	Model Per	Optimal seed		
Discovery sample	0 790		Hippocompus	0 5 4 7	1 095 07	Transversetemperal	0.660	6 16E 10	Hippocompus	
(n=1,792, both early & chronic)	0.769	1.00E-18	hippocampus	0.547	1.082-07	Transversetempora	0.009	0.10E-12	hippocampus	
Validation sample	0.707 1.09E-13		Dorooporoulorio	0 609	2 10E 12	Middletemperal	0 700		Hippocompus	
(n=4,474, predominant chronic)			Parsopercularis	0.090	3.19E-13	Miduletemporal	0.725	1.720-14	Hippocampus	
First-episode subsample			Darahinnaamnal			Thelemus	0 504		Hippocompus	
(n=709)	0.721 2.09E-14		Faranippocanipai	0.407	4.77 E-00	Thalamus	0.504	1.902-00	Hippocampus	
Drug-naive subsample	0.432 6.01E-05		Darahinnaaamnal	0 422		Thelemus	0 421	6 225 05	Hippocompus	
(n=481)			Paranippocanipai	0.432	0.01E-05	Thalamus	0.431	0.23E-05	Hippocampus	

\* these p values are still significant through spatial permutation test and multiple comparisons correction by FDR.

	Discovery sample			Va	Validation sample			ES subsamp	le	Drug-naive subsample			
Structure		(n=1,799)			(n=4,474)			(n=709)			(n=481)		
	NDM_MC	NDM_SC	NDM_FC	NDM_MC	NDM_SC	NDM_FC	NDM_MC	NDM_SC	NDM_FC	NDM_MC	NDM_SC	NDM_FC	
Bilaterial Thalamus	0.706	0.294	0.527	0.438	0.217	0.459	0.506	0.487	0.380	0.474	0.432	0.320	
Bilaterial Caudate	0.368	0.276	0.378	0.209	0.018	0.361	0.446	-0.090	0.083	0.381	-0.122	0.045	
Bilaterial Putamen	0.360	0.285	0.389	0.162	0.085	0.283	0.383	0.055	0.052	0.368	0.017	0.044	
Bilaterial Pallidum	0.363	0.282	-0.001	0.150	0.107	-0.083	0.370	0.153	0.064	0.338	0.110	0.057	
Bilaterial Hippocampus	0.789	0.340	0.669	0.593	0.183	0.723	0.694	0.225	0.504	0.623	0.210	0.431	
Bilaterial Amygdala	0.719	0.339	0.153	0.526	0.267	0.038	0.641	0.257	0.108	0.531	0.225	0.073	
Bilaterial Accumbens	0.372	0.185	-0.113	0.237	-0.014	-0.099	0.380	0.075	0.095	0.369	0.060	0.104	
Bilaterial bankssts	0.700	0.367	0.471	0.674	0.551	0.568	0.577	0.241	0.070	0.456	0.171	0.003	
Bilaterial caudalanteriorcingulate	0.570	-0.068	0.460	0.339	-0.165	0.354	0.457	0.045	0.119	0.451	0.080	0.070	
Bilaterial caudalmiddlefrontal	0.640	0.226	0.469	0.582	0.325	0.555	0.439	0.053	0.104	0.384	-0.016	0.019	
Bilaterial cuneus	0.491	0.136	0.455	0.374	0.217	0.338	0.470	0.308	0.231	0.396	0.291	0.204	
Bilaterial entorhinal	-0.026	0.008	0.341	0.505	0.209	0.250	0.423	0.227	0.199	0.392	0.216	0.158	
Bilaterial fusiform	0.765	0.322	0.545	0.618	0.287	0.538	0.573	0.261	0.365	0.524	0.240	0.318	
Bilaterial inferiorparietal	0.727	0.325	0.493	0.616	0.604	0.556	0.576	0.261	0.203	0.466	0.185	0.135	
Bilaterial inferiortemporal	0.749	0.341	0.523	0.609	0.497	0.597	0.606	0.315	0.367	0.455	0.276	0.283	
Bilaterial isthmuscingulate	0.614	0.290	0.410	0.523	0.020	0.314	0.622	0.245	0.147	0.526	0.286	0.119	
Bilaterial lateraloccipital	0.586	0.320	0.546	0.558	0.321	0.455	0.489	0.304	0.319	0.460	0.269	0.271	
Bilaterial lateralorbitofrontal	0.705	0.256	0.480	0.610	0.103	0.629	0.601	-0.010	0.059	0.126	-0.039	-0.006	
Bilaterial lingual	0.476	0.238	0.510	0.358	0.225	0.475	0.465	0.274	0.300	0.450	0.253	0.253	
Bilaterial medialorbitofrontal	0.696	0.081	0.283	0.502	-0.116	0.329	0.506	-0.084	0.002	0.343	-0.069	-0.041	
Bilaterial middletemporal	0.734	0.306	0.501	0.595	0.698	0.532	0.606	0.303	0.076	0.201	0.245	0.006	
Bilaterial parahippocampal	0.504	0.231	0.480	0.571	0.191	0.329	0.721	0.241	0.261	0.675	0.246	0.210	
Bilaterial paracentral	0.687	0.343	0.502	0.457	-0.021	0.420	0.486	0.076	0.217	0.440	0.052	0.176	
Bilaterial parsopercularis	0.687	0.150	0.477	0.707	0.346	0.559	0.401	-0.031	0.039	0.212	-0.103	-0.011	
Bilaterial parsorbitalis	0.661	0.112	0.385	0.621	0.136	0.641	0.471	-0.104	0.017	0.439	-0.147	-0.061	
Bilaterial parstriangularis	0.646	0.117	0.444	0.668	0.187	0.690	0.397	-0.062	0.033	0.151	-0.114	-0.051	
Bilaterial pericalcarine	0.484	0.081	0.429	0.370	0.216	0.320	0.448	0.305	0.203	0.397	0.288	0.182	
Bilaterial postcentral	0.726	0.368	0.530	0.549	0.224	0.435	0.630	0.086	0.337	0.551	0.031	0.284	
Bilaterial posteriorcingulate	0.676	0.279	0.510	0.464	-0.130	0.485	0.435	0.084	0.243	0.518	0.104	0.172	

Subplemental V Table 33, Nodel benonnance with each brain region as the seed of hetwork diffusion model
---

Bilaterial precentral	0.717	0.330	0.534	0.580	0.197	0.467	0.606	0.076	0.294	0.291	0.038	0.238
Bilaterial precuneus	0.684	0.292	0.501	0.591	0.125	0.451	0.580	0.283	0.312	0.239	0.285	0.243
Bilaterial rostralanteriorcingulate	0.585	-0.056	0.387	0.386	-0.211	0.284	0.495	-0.062	0.038	0.410	-0.028	0.007
Bilaterial rostralmiddlefrontal	0.674	0.283	0.479	0.533	0.233	0.526	0.488	-0.088	0.084	0.098	-0.142	0.011
Bilaterial superiorfrontal	0.726	0.303	0.497	0.581	-0.096	0.583	0.515	-0.100	0.134	-0.026	-0.084	0.072
Bilaterial superiorparietal	0.672	0.289	0.486	0.537	0.246	0.398	0.559	0.278	0.218	0.493	0.243	0.177
Bilaterial superiortemporal	0.755	0.330	0.513	0.635	0.449	0.678	0.581	0.234	0.305	0.127	0.177	0.216
Bilaterial supramarginal	0.749	0.324	0.508	0.619	0.501	0.492	0.596	0.141	0.090	0.539	0.065	0.046
Bilaterial frontalpole	0.623	-0.071	0.248	0.433	-0.054	0.305	0.471	-0.091	0.034	0.263	-0.088	-0.003
Bilaterial temporalpole	-0.152	0.060	0.315	0.484	0.395	0.314	0.337	0.285	0.145	0.321	0.249	0.098
Bilaterial transversetemporal	0.740	0.547	0.503	0.578	0.439	0.459	0.591	0.205	0.242	0.413	0.130	0.185
Bilaterial insula	0.666	0.326	0.564	0.591	0.465	0.464	0.590	-0.010	0.171	0.034	-0.085	0.143

Cappionion				) buood opun			spinoina popi		
(a) NDM subgroup	Model Performance (r)	Ν	Age(years)	Female N (%)	PANSS N	PANSS_Pos	PANSS_Neg	PANSS_Gen	PANSS_Tot
SZnonNDM	0.42	500(27.9%)	29.1(11.2)	182(36.4%)	314	19.4(7.0)*	17.4(7.4)	36.8(10.4)*	73.6(20.4)*
SZNDM	0.48	1292(72.1%)	30.2(12.1)	578(44.7%)	895	18.5(6.8)*	17.2(7.7)	34.9(10.4)*	70.6(20.7)*
(b) Spatial phenotype	Model Performance (r)	Ν							
Temporal Cortex Phenotype	0.46	434(24.2%)	31.1(12.4)	191(44.0%)	301	18.3(6.8)	17.0(7.7)	34.1(10.3)*	69.3(20.1)*
Frontal Cortex Phenotype	0.50	244(13.6%)	28.3(11.2)	112(45.9%)	169	19.0(6.6)	17.5(7.0)	35.2(10.1)	71.8(19.8)
Cingulate-Insula Phenotype	0.49	143(8.0%)	30.5(12.7)	59(41.3%)	87	19.0(6.9)	17.9(7.4)	36.6(9.6)	73.5(19.3)
Basal Ganglia Phenotype	0.47	132(7.4%)	31.5(13.0)	59(44.7%)	94	17.4(7.3)*	17.0(8.3)	34.9(12.1)	69.3(23.9)
Occipital Cortex Phenotype	0.47	113(6.3%)	30.9(12.4)	58(51.3%)	83	18.9(6.5)	18.2(8.5)	36.3(11.6)	73.3(23.5)
Parietal Cortex Phenotype	0.49	102(5.7%)	28.6(11.2)	54(52.9%)	64	18.6(6.9)	16.6(8.8)	33.8(9.2)	69.0(19.1)
Somatosensory Cortex Phenotype	0.49	72(4.0%)	29.1(12.0)	25(34.7%)	53	18.5(7.2)	17.1(7.7)	35.3(10.1)	70.8(20.7)
Thalamus Phenotype	0.46	52(2.9%)	31.3(12.2)	20(38.5%)	44	18.1(6.1)	16.6(7.6)	34.4(10.0)	69.1(20.4)

Supplementary Table S10. Network diffusion model (NDM)-based 'spatial' phenotypes in schizophrenia population

\* P<0.05 from two-tailed two-sample t test between each subgroup and all other subgroups.

Supplementary Lable S11. Regional comparisons of drav matter volume between each spatial phenotype in schizophrenia and nea
---

			Sup	plemei	ntary Table	e S11. R	Regiona	l comparis	ions of	f gray i	matter volu	ume be	tween	each spatia	al phei	notype	in schizop	ohrenia	a and I	nealthy co	ntrols							
	Tei	mporal Corte	х	F	Frontal Corte	х	Ci	ngulate-Insu	E	Basal Ganglia			ccipital Corte	ex	Р	arietal Corte	x	S	Somatosensory Thalamus					nonNDM				
Region	Phenotype			Phenotype			Phenotype			Phenotype			Phenotype				Phenotype		Cortex Phenotype				Phenotype		Phenotype			
-	Т	Р	ES	Т	Р	ES	Т	Р	ES	Т	Р	ES	Т	Р	ES	Т	Р	ES	Т	Р	ES	Т	Р	ES	Т	Р	ES	
L_thalamus	-5.4	6.1E-08	-0.5	-6.8	2.0E-11	-0.5	-5.6	1.9E-08	-0.3	-5.3	1.2E-07	-0.5	-2.8	5.5E-03	-0.3	-2.6	1.0E-02	-0.3	-1.0	3.2E-01	-0.1	-7.9	5.6E-15	-1.1	-1.9	5.7E-02	-0.1	
L_caudate	-6.0	2.9E-09	-0.5	-2.7	7.9E-03	-0.2	3.8	1.7E-04	0.2	0.2	8.4E-01	0.0	1.3	1.8E-01	0.1	2.9	3.6E-03	0.3	2.9	4.2E-03	0.3	-1.6	1.1E-01	-0.2	2.9	4.2E-03	0.1	
L_putamen	-5.4	8.4E-08	-0.5	0.5	6.5E-01	0.0	2.4	1.5E-02	0.1	-0.6	5.5E-01	-0.1	0.3	7.7E-01	0.0	2.6	1.0E-02	0.3	1.4	1.7E-01	0.2	-0.7	4.7E-01	-0.1	0.9	3.5E-01	0.0	
L_pallidum	-3.2	1.6E-03	-0.3	3.8	1.5E-04	0.3	4.7	2.4E-06	0.3	1.8	7.3E-02	0.2	2.4	1.5E-02	0.2	1.7	9.0E-02	0.2	2.3	2.0E-02	0.3	-1.3	2.1E-01	-0.2	1.8	6.9E-02	0.1	
L_hippocampus	-3.6	3.7E-04	-0.3	-6.6	4.3E-11	-0.5	-11.8	0.0E+00	-0.6	-4.4	1.3E-05	-0.4	-5.8	8.6E-09	-0.6	-2.2	2.5E-02	-0.2	-2.9	3.9E-03	-0.3	-4.1	3.6E-05	-0.6	-5.9	4.9E-09	-0.3	
L_amygdala	-3.6	3.6E-04	-0.3	-1.9	5.8E-02	-0.1	-8.4	1.1E-16	-0.5	-2.2	3.1E-02	-0.2	-2.0	4.5E-02	-0.2	-0.9	3.4E-01	-0.1	-2.2	2.6E-02	-0.3	-2.3	2.4E-02	-0.3	-4.2	2.7E-05	-0.2	
L_accumbens	-8.5	0.0E+00	-0.8	-4.3	1.7E-05	-0.3	-2.5	1.1E-02	-0.1	-2.6	1.0E-02	-0.2	-1.9	5.5E-02	-0.2	0.2	8.2E-01	0.0	0.1	9.2E-01	0.0	-4.5	9.1E-06	-0.6	-3.1	2.3E-03	-0.2	
R_thalamus	-6.6	5.7E-11	-0.6	-5.5	4.8E-08	-0.4	-6.3	2.9E-10	-0.3	-5.4	8.0E-08	-0.5	-3.8	1.5E-04	-0.4	-2.7	7.4E-03	-0.3	-1.5	1.3E-01	-0.2	-7.4	2.3E-13	-1.0	-3.2	1.6E-03	-0.2	
R_caudate	-5.8	9.0E-09	-0.5	-3.1	1.9E-03	-0.2	4.4	1.2E-05	0.2	-0.4	7.0E-01	0.0	2.4	1.6E-02	0.2	3.1	2.1E-03	0.3	2.8	4.9E-03	0.3	-1.4	1.5E-01	-0.2	3.5	4.1E-04	0.2	
R_putamen	-4.2	3.2E-05	-0.4	0.9	3.6E-01	0.1	2.5	1.4E-02	0.1	0.1	9.2E-01	0.0	1.3	1.9E-01	0.1	2.5	1.3E-02	0.3	1.7	8.7E-02	0.2	-0.8	4.1E-01	-0.1	1.1	2.9E-01	0.1	
R_pallidum	-3.1	2.3E-03	-0.3	3.5	5.0E-04	0.2	4.8	2.1E-06	0.3	1.1	2.5E-01	0.1	3.0	3.2E-03	0.3	2.9	4.1E-03	0.3	2.7	7.2E-03	0.3	-2.1	3.7E-02	-0.3	3.6	2.7E-04	0.2	
R_hippocampus	-4.2	3.4E-05	-0.4	-4.9	1.2E-06	-0.3	-10.8	0.0E+00	-0.6	-4.7	3.0E-06	-0.4	-4.4	9.6E-06	-0.4	-2.2	2.6E-02	-0.2	-2.5	1.3E-02	-0.3	-3.5	5.6E-04	-0.5	-5.0	6.4E-07	-0.3	
R_amygdala	-2.8	5.9E-03	-0.3	-1.3	1.8E-01	-0.1	-5.6	2.9E-08	-0.3	-2.2	2.8E-02	-0.2	-2.3	2.3E-02	-0.2	-0.8	4.4E-01	-0.1	-1.6	1.1E-01	-0.2	-2.0	4.1E-02	-0.3	-2.0	4.4E-02	-0.1	
R_accumbens	-9.9	0.0E+00	-0.9	-5.4	8.8E-08	-0.4	-2.7	6.8E-03	-0.1	-2.7	7.4E-03	-0.2	-1.8	7.8E-02	-0.2	-0.6	5.2E-01	-0.1	-0.3	7.5E-01	0.0	-4.2	2.4E-05	-0.6	-3.5	4.1E-04	-0.2	
L_bankssts	0.2	8.6E-01	0.0	-3.3	8.8E-04	-0.2	-4.3	1.6E-05	-0.2	-1.7	9.1E-02	-0.1	1.1	2.6E-01	0.1	-3.1	1.9E-03	-0.3	-0.6	5.3E-01	-0.1	0.3	7.6E-01	0.0	-1.4	1.7E-01	-0.1	
L_caudalanteriorcingulate	-1.1	2.6E-01	-0.1	-3.0	3.0E-03	-0.2	0.0	9.6E-01	0.0	-4.4	9.4E-06	-0.4	0.7	4.7E-01	0.1	-0.2	8.2E-01	0.0	-2.1	3.9E-02	-0.2	-0.2	8.2E-01	0.0	-2.2	3.0E-02	-0.1	
	-3.3	1.1E-03	-0.3	-6.5	1.7E-11	-0.5	-2.0	4.2E-02	-0.1	-3.7	2.1E-04	-0.3	-1.2	2.3E-01	-0.1	-2.3	2.1E-02	-0.2	-3.0	3.1E-03	-0.4	-2.0	4.7E-02	-0.3	0.9	3.5E-01	0.0	
L_cuneus	-1.2	2.4E-01	-0.1	1.0	1.0E+00	0.0	-0.3	1.0E-01	0.0	0.2	0.1E-01	0.0	-10.0	0.0E+00	-1.0	-4.4	1.3E-05	-0.4	1.2	2.2E-01	0.1	-2.4	1.5E-02	-0.3	-1.1	2.9E-01	-0.1	
	0.5	1 45 02	0.0	1.9 5.7	1 9 5 09	0.1	-4.5	0.05.00	-0.2	-0.9	3.9E-01	-0.1	-0.7	4.7E-01	-0.1	17	9.12-01	0.0	1.4	1.00-01	0.2	0.0	4.1E-01	0.1	-2.0	4.9E-03	-0.1	
	-2.5	1.4C-02	-0.2	-5.7	2.7E-00	-0.4	-9.0	8.8E-05	-0.5	-3.0	2.5E-05	-0.3	-2.3	2.1E-02	-0.2	-1.7	6.9E-04	-0.2	-0.3	7.3E-01	-0.2	-0.7	3.1E-01	-0.1	-2.1	3.3E-02 7.3E-03	-0.1	
L_inferiortemporal	-2.4	1.8E-02	-0.1	-6.0	1.8E-09	-0.4	-6.7	0.0⊑-00	-0.2	-4.3	1.0E-05	-0.4	-2.0	4.0E-02	-0.2	-1.9	5.8E-02	-0.2	-0.8	4 1E-01	-0.1	1 7	4.3E-01 8.6E-02	0.1	-2.7	4.5E-03	-0.1	
	0.4	6.8E-01	0.0	-2.2	3 1E-02	-0.1	-1 1	2.6E-01	-0.1	-4.3	1.7E-05	-0.4	-4.2	2 4E-05	-0.4	-4 7	3.0E-02	-0.5	0.0	4.1E 01	0.1	-1.5	0.0E 02 1.3E-01	-0.2	-0.1	9.5E-01	0.0	
L lateraloccipital	-3.0	2.4E-03	-0.3	-4.7	2.5E-06	-0.3	-3.7	1.8E-04	-0.2	-2.6	8.3E-03	-0.2	-7.0	3.4E-12	-0.7	-4.4	1.4E-05	-0.4	-3.0	3.1E-03	-0.4	-1.5	1.4E-01	-0.2	-1.9	6.2E-02	-0.1	
L lateralorbitofrontal	-3.4	7.5E-04	-0.3	-9.9	0.0E+00	-0.7	-3.9	9.7E-05	-0.2	-5.7	1.3E-08	-0.5	-0.8	4.0E-01	-0.1	-2.6	9.4E-03	-0.3	-3.9	1.2E-04	-0.5	-0.7	4.7E-01	-0.1	-0.8	4.0E-01	0.0	
_ L_lingual	-2.6	8.6E-03	-0.2	-0.5	6.3E-01	0.0	-2.7	7.8E-03	-0.1	-1.0	3.1E-01	-0.1	-10.7	0.0E+00	-1.0	-3.9	1.1E-04	-0.4	-1.0	3.4E-01	-0.1	-3.2	1.3E-03	-0.5	-1.8	7.8E-02	-0.1	
L_medialorbitofrontal	-1.1	2.7E-01	-0.1	-6.8	1.3E-11	-0.5	-2.6	1.0E-02	-0.1	-2.0	4.6E-02	-0.2	0.9	3.9E-01	0.1	0.0	9.7E-01	0.0	-2.3	2.5E-02	-0.3	-0.4	7.2E-01	-0.1	-0.5	6.1E-01	0.0	
L_middletemporal	-2.3	2.0E-02	-0.2	-8.2	5.6E-16	-0.6	-5.7	1.7E-08	-0.3	-4.8	2.2E-06	-0.4	-2.5	1.3E-02	-0.2	-2.6	8.9E-03	-0.3	-0.4	7.3E-01	0.0	0.3	7.9E-01	0.0	-0.8	4.2E-01	0.0	
L_parahippocampal	0.3	7.8E-01	0.0	0.0	1.0E+00	0.0	-7.8	7.9E-15	-0.4	-1.1	2.7E-01	-0.1	-1.9	6.3E-02	-0.2	0.3	7.7E-01	0.0	-0.8	4.3E-01	-0.1	-1.1	2.6E-01	-0.2	-2.7	7.3E-03	-0.1	
L_paracentral	-1.8	7.7E-02	-0.2	-5.6	3.1E-08	-0.4	-2.6	1.1E-02	-0.1	-3.2	1.6E-03	-0.3	-0.1	9.5E-01	0.0	-3.0	3.2E-03	-0.3	-5.4	8.5E-08	-0.6	-2.2	2.6E-02	-0.3	0.1	8.8E-01	0.0	
L_parsopercularis	-3.0	3.0E-03	-0.3	-7.3	5.0E-13	-0.5	-1.3	1.9E-01	-0.1	-3.8	1.6E-04	-0.3	-2.4	1.7E-02	-0.2	-1.4	1.7E-01	-0.1	-1.9	5.5E-02	-0.2	-1.0	3.2E-01	-0.1	-1.4	1.5E-01	-0.1	
L_parsorbitalis	-2.8	4.7E-03	-0.3	-9.2	0.0E+00	-0.6	-2.8	5.5E-03	-0.2	-2.5	1.4E-02	-0.2	-2.3	2.2E-02	-0.2	-0.5	6.0E-01	-0.1	-2.3	2.4E-02	-0.3	-0.6	5.6E-01	-0.1	-0.1	9.2E-01	0.0	
L_parstriangularis	-2.0	4.5E-02	-0.2	-7.7	1.8E-14	-0.5	-1.9	6.2E-02	-0.1	-2.6	8.3E-03	-0.2	-1.9	5.7E-02	-0.2	-0.9	3.9E-01	-0.1	0.4	6.9E-01	0.0	-2.0	4.3E-02	-0.3	-1.0	3.2E-01	-0.1	
L_pericalcarine	0.7	5.1E-01	0.1	2.2	2.5E-02	0.2	2.4	1.5E-02	0.1	-0.3	7.8E-01	0.0	-9.8	0.0E+00	-1.0	-2.0	4.9E-02	-0.2	0.8	4.3E-01	0.1	-1.9	5.5E-02	-0.3	-0.4	6.7E-01	0.0	
L_postcentral	-3.7	2.2E-04	-0.3	-5.4	9.2E-08	-0.4	-6.6	5.7E-11	-0.4	-4.7	3.1E-06	-0.4	-2.2	2.8E-02	-0.2	-4.7	3.0E-06	-0.5	-5.6	3.2E-08	-0.7	-1.8	6.9E-02	-0.3	-0.8	4.3E-01	0.0	
L_posteriorcingulate	-2.3	2.1E-02	-0.2	-5.6	2.0E-08	-0.4	-3.2	1.5E-03	-0.2	-5.6	2.0E-08	-0.5	0.4	6.8E-01	0.0	-3.9	8.6E-05	-0.4	-2.7	8.0E-03	-0.3	-1.8	7.0E-02	-0.3	-1.0	3.0E-01	-0.1	
L_precentral	-4.4	1.1E-05	-0.4	-6.7	3.2E-11	-0.5	-5.0	5.2E-07	-0.3	-4.5	7.8E-06	-0.4	-2.7	7.7E-03	-0.3	-4.7	2.9E-06	-0.5	-5.9	5.6E-09	-0.7	-3.4	6.5E-04	-0.5	-2.4	1.7E-02	-0.1	
L_precuneus	-3.1	2.0E-03	-0.3	-4.8	2.1E-06	-0.3	-2.4	1.5E-02	-0.1	-5.6	3.0E-08	-0.5	-1.3	1.8E-01	-0.1	-6.1	1.2E-09	-0.6	-1.1	2.9E-01	-0.1	-1.0	3.3E-01	-0.1	-0.3	7.5E-01	0.0	
L_rostralanteriorcingulate	-2.3	2.3E-02	-0.2	-4.1	3.6E-05	-0.3	-1.7	8.2E-02	-0.1	-5.6	2.5E-08	-0.5	-0.2	8.2E-01	0.0	-0.2	8.7E-01	0.0	-1.3	1.8E-01	-0.2	0.7	5.1E-01	0.1	-2.0	4.1E-02	-0.1	
L_rostralmiddlefrontal	-2.2	2.6E-02	-0.2	-9.8	0.0E+00	-0.7	-2.8	6.0E-03	-0.1	-5.2	2.3E-07	-0.5	-2.2	2.6E-02	-0.2	-0.5	5.9E-01	-0.1	-0.6	5.5E-01	-0.1	0.8	4.5E-01	0.1	-1.0	3.2E-01	-0.1	
L_superiorfrontal	-3.1	2.2E-03	-0.3	-12.3	0.0E+00	-0.8	-5.1	4.4E-07	-0.3	-6.3	3.1E-10	-0.6	-2.9	4.3E-03	-0.3	-4.1	4.9E-05	-0.4	-2.7	6.7E-03	-0.3	-1.0	3.4E-01	-0.1	-1.0	3.3E-01	-0.1	
L_superiorparietal	-2.5	1.4E-02	-0.2	-3.5	5.6E-04	-0.2	-1.7	8.0E-02	-0.1	-3.8	1.6E-04	-0.3	-0.3	7.3E-01	0.0	-5.1	4.9E-07	-0.5	-1.7	9.4E-02	-0.2	-1.5	1.3E-01	-0.2	-0.9	3.5E-01	0.0	
L_superiortemporal	-2.6	9.2E-03	-0.2	-7.1	2.2E-12	-0.5	-7.7	2.5E-14	-0.4	-4.4	1.1E-05	-0.4	-0.7	4.9E-01	-0.1	-2.7	7.8E-03	-0.3	-3.5	5.1E-04	-0.4	-1.6	1.2E-01	-0.2	-2.5	1.4E-02	-0.1	
L_supramarginal	-1.7	8.4E-02	-0.2	-4.6	4.9E-06	-0.3	-5.3	1.4E-07	-0.3	-4.8	1.4E-06	-0.4	-1.9	5.9E-02	-0.2	-4.6	4.5E-06	-0.5	-1.8	6.8E-02	-0.2	-2.7	6.2E-03	-0.4	-2.1	3.7E-02	-0.1	
L_trontalpole	1.8	6.8E-02	0.2	-8.3	2.2E-16	-0.6	0.5	6.0E-01	0.0	-0.9	3.7E-01	-0.1	-1.2	2.3E-01	-0.1	0.2	8.4E-01	0.0	0.3	7.9E-01	0.0	1.3	1.9E-01	0.2	-2.0	4.4E-02	-0.1	

L_temporalpole	1.4	1.6E-01	0.1	1.7	9.2E-02	0.1	-5.0	6.5E-07	-0.3	0.4	7.1E-01	0.0	0.8	4.1E-01	0.1	3.4	6.1E-04	0.4	0.9	3.7E-01	0.1	1.1	2.8E-01	0.2	-1.5	1.3E-01	-0.1
L_transversetemporal	-1.6	1.2E-01	-0.1	-2.8	4.6E-03	-0.2	-4.5	7.7E-06	-0.2	-3.2	1.4E-03	-0.3	-0.9	3.7E-01	-0.1	-3.1	2.1E-03	-0.3	-2.7	8.0E-03	-0.3	-1.6	1.2E-01	-0.2	-1.5	1.4E-01	-0.1
L_insula	-3.8	1.6E-04	-0.3	-7.6	3.8E-14	-0.5	-5.1	2.9E-07	-0.3	-6.9	6.9E-12	-0.6	-1.7	8.6E-02	-0.2	-2.1	3.8E-02	-0.2	-2.1	3.6E-02	-0.3	-1.9	5.5E-02	-0.3	-3.5	4.7E-04	-0.2
R_bankssts	-2.9	3.8E-03	-0.3	-5.0	5.4E-07	-0.3	-5.1	3.7E-07	-0.3	-2.9	3.5E-03	-0.3	-1.0	3.3E-01	-0.1	-1.8	7.1E-02	-0.2	-2.7	6.1E-03	-0.3	-0.2	8.7E-01	0.0	-0.5	5.8E-01	0.0
R_caudalanteriorcingulate	-3.0	3.1E-03	-0.3	-2.2	2.8E-02	-0.2	0.0	9.9E-01	0.0	-6.8	1.5E-11	-0.6	1.0	3.0E-01	0.1	1.6	1.1E-01	0.2	-1.7	8.3E-02	-0.2	0.5	5.9E-01	0.1	-2.2	3.2E-02	-0.1
R_caudalmiddlefrontal	-2.6	1.0E-02	-0.2	-6.3	4.7E-10	-0.4	-2.3	2.0E-02	-0.1	-3.6	2.9E-04	-0.3	-1.1	2.6E-01	-0.1	-1.8	6.8E-02	-0.2	-2.4	1.5E-02	-0.3	-2.3	2.0E-02	-0.3	1.5	1.3E-01	0.1
R_cuneus	-1.4	1.6E-01	-0.1	-0.8	4.0E-01	-0.1	-1.5	1.2E-01	-0.1	-0.3	7.8E-01	0.0	-8.9	0.0E+00	-0.9	-4.5	7.8E-06	-0.5	-0.8	4.4E-01	-0.1	-1.6	1.1E-01	-0.2	-1.9	5.5E-02	-0.1
R_entorhinal	1.1	2.9E-01	0.1	1.5	1.4E-01	0.1	-5.7	1.2E-08	-0.3	-0.1	9.4E-01	0.0	0.6	5.8E-01	0.1	1.1	2.9E-01	0.1	0.9	3.6E-01	0.1	1.1	2.9E-01	0.2	-2.2	3.1E-02	-0.1
R_fusiform	-2.8	5.2E-03	-0.3	-5.0	7.4E-07	-0.3	-9.9	0.0E+00	-0.5	-3.3	1.2E-03	-0.3	-3.0	2.4E-03	-0.3	-2.0	4.3E-02	-0.2	-3.4	7.3E-04	-0.4	-0.6	5.4E-01	-0.1	-2.7	6.4E-03	-0.1
R_inferiorparietal	-0.6	5.8E-01	-0.1	-6.8	1.3E-11	-0.5	-5.9	4.3E-09	-0.3	-4.7	3.4E-06	-0.4	-1.9	5.5E-02	-0.2	-4.1	4.3E-05	-0.4	-0.8	4.0E-01	-0.1	-2.0	4.5E-02	-0.3	-1.7	9.6E-02	-0.1
R_inferiortemporal	-2.3	2.3E-02	-0.2	-5.3	1.0E-07	-0.4	-8.5	0.0E+00	-0.5	-3.0	3.2E-03	-0.3	0.0	9.7E-01	0.0	-1.4	1.5E-01	-0.1	-1.2	2.3E-01	-0.1	1.2	2.3E-01	0.2	-3.8	1.7E-04	-0.2
R_isthmuscingulate	0.4	6.8E-01	0.0	-2.2	2.7E-02	-0.2	-2.4	1.4E-02	-0.1	-4.3	1.5E-05	-0.4	-4.7	2.9E-06	-0.5	-5.1	4.5E-07	-0.5	0.8	4.1E-01	0.1	-1.2	2.4E-01	-0.2	-1.9	6.1E-02	-0.1
R_lateraloccipital	-1.8	7.9E-02	-0.2	-3.7	2.2E-04	-0.3	-4.0	5.4E-05	-0.2	-3.2	1.4E-03	-0.3	-7.7	2.7E-14	-0.7	-4.3	1.5E-05	-0.4	-3.8	1.6E-04	-0.5	-2.0	4.7E-02	-0.3	-1.9	6.1E-02	-0.1
R_lateralorbitofrontal	-2.3	2.4E-02	-0.2	-9.0	0.0E+00	-0.6	-2.7	6.4E-03	-0.1	-4.8	1.7E-06	-0.4	-1.3	1.8E-01	-0.1	-1.6	1.1E-01	-0.2	-2.5	1.1E-02	-0.3	1.3	1.8E-01	0.2	-1.1	2.9E-01	-0.1
R_lingual	-1.7	9.6E-02	-0.2	-0.6	5.2E-01	0.0	-1.6	1.1E-01	-0.1	-1.9	5.1E-02	-0.2	-11.0	0.0E+00	-1.1	-3.7	2.2E-04	-0.4	-1.2	2.1E-01	-0.1	-2.5	1.2E-02	-0.4	-1.5	1.3E-01	-0.1
R_medialorbitofrontal	-4.2	2.7E-05	-0.4	-9.1	0.0E+00	-0.6	-4.1	3.9E-05	-0.2	-5.1	3.7E-07	-0.4	-2.0	4.1E-02	-0.2	-1.0	3.0E-01	-0.1	-1.4	1.6E-01	-0.2	0.7	4.8E-01	0.1	-2.5	1.4E-02	-0.1
R_middletemporal	-2.0	5.0E-02	-0.2	-8.3	3.3E-16	-0.6	-6.8	1.4E-11	-0.4	-4.1	3.9E-05	-0.4	-2.5	1.2E-02	-0.2	-3.0	2.4E-03	-0.3	-0.5	6.4E-01	-0.1	-0.1	9.1E-01	0.0	-0.8	4.1E-01	0.0
R_parahippocampal	-1.4	1.6E-01	-0.1	0.2	8.2E-01	0.0	-7.4	2.5E-13	-0.4	-1.5	1.4E-01	-0.1	-3.3	8.9E-04	-0.3	-1.5	1.2E-01	-0.2	-1.4	1.6E-01	-0.2	-2.6	8.9E-03	-0.4	-2.9	3.8E-03	-0.1
R_paracentral	-3.8	1.6E-04	-0.3	-5.2	2.6E-07	-0.4	-4.1	4.9E-05	-0.2	-5.3	1.3E-07	-0.5	-0.6	5.2E-01	-0.1	-1.9	5.4E-02	-0.2	-6.4	2.0E-10	-0.8	-3.9	8.4E-05	-0.6	-0.2	8.2E-01	0.0
R_parsopercularis	-2.3	2.4E-02	-0.2	-7.9	4.0E-15	-0.5	-1.7	8.9E-02	-0.1	-3.3	1.1E-03	-0.3	-2.5	1.4E-02	-0.2	-0.1	9.4E-01	0.0	-0.8	4.3E-01	-0.1	-1.1	2.5E-01	-0.2	-1.9	5.6E-02	-0.1
R_parsorbitalis	-3.1	2.3E-03	-0.3	-9.3	0.0E+00	-0.6	-1.5	1.5E-01	-0.1	-1.2	2.4E-01	-0.1	-2.3	2.0E-02	-0.2	0.6	5.3E-01	0.1	-0.5	6.5E-01	-0.1	2.6	9.0E-03	0.4	-0.8	4.2E-01	0.0
R_parstriangularis	-2.0	5.1E-02	-0.2	-7.8	1.0E-14	-0.5	-2.0	4.2E-02	-0.1	-2.5	1.3E-02	-0.2	-1.6	1.0E-01	-0.2	1.0	3.2E-01	0.1	2.1	3.3E-02	0.3	0.7	4.8E-01	0.1	-1.6	1.2E-01	-0.1
R_pericalcarine	1.0	3.2E-01	0.1	2.3	2.1E-02	0.2	2.7	7.9E-03	0.1	0.2	8.3E-01	0.0	-9.7	0.0E+00	-1.0	-2.1	4.0E-02	-0.2	0.6	5.5E-01	0.1	-1.8	7.7E-02	-0.2	-0.3	7.7E-01	0.0
R_postcentral	-0.6	5.7E-01	-0.1	-4.6	5.1E-06	-0.3	-3.6	3.1E-04	-0.2	-3.9	8.3E-05	-0.3	-2.6	9.4E-03	-0.3	-3.8	1.3E-04	-0.4	-6.8	1.7E-11	-0.8	-2.6	8.3E-03	-0.4	-1.6	1.0E-01	-0.1
R_posteriorcingulate	-3.9	8.2E-05	-0.4	-5.5	4.0E-08	-0.4	-4.1	4.2E-05	-0.2	-8.5	0.0E+00	-0.7	-1.1	2.7E-01	-0.1	-2.2	2.9E-02	-0.2	-4.5	6.5E-06	-0.5	-1.8	6.8E-02	-0.3	-1.8	6.8E-02	-0.1
R_precentral	-1.5	1.3E-01	-0.1	-6.0	2.8E-09	-0.4	-4.4	1.1E-05	-0.2	-4.6	5.4E-06	-0.4	-1.9	6.4E-02	-0.2	-4.0	7.1E-05	-0.4	-6.8	1.1E-11	-0.8	-3.6	2.8E-04	-0.5	-1.0	3.0E-01	-0.1
R_precuneus	-1.9	5.5E-02	-0.2	-5.0	7.9E-07	-0.3	-2.9	4.1E-03	-0.2	-5.7	1.6E-08	-0.5	-2.1	3.3E-02	-0.2	-8.1	7.8E-16	-0.8	-1.7	8.3E-02	-0.2	-1.3	1.8E-01	-0.2	-0.7	4.9E-01	0.0
R_rostralanteriorcingulate	-2.1	3.5E-02	-0.2	-4.8	1.4E-06	-0.3	-2.9	4.3E-03	-0.2	-7.7	3.0E-14	-0.7	1.3	2.1E-01	0.1	0.7	4.6E-01	0.1	-2.5	1.1E-02	-0.3	0.8	4.1E-01	0.1	-2.0	4.2E-02	-0.1
R_rostralmiddlefrontal	-2.5	1.2E-02	-0.2	-8.5	0.0E+00	-0.6	-1.8	7.4E-02	-0.1	-3.8	1.6E-04	-0.3	-1.6	1.1E-01	-0.2	-0.2	8.7E-01	0.0	1.9	5.5E-02	0.2	1.7	8.6E-02	0.2	-1.5	1.4E-01	-0.1
R_superiorfrontal	-4.1	4.0E-05	-0.4	-11.2	0.0E+00	-0.8	-4.8	1.9E-06	-0.3	-5.1	3.3E-07	-0.4	-2.4	1.8E-02	-0.2	-2.5	1.3E-02	-0.3	-1.2	2.2E-01	-0.1	-1.6	1.0E-01	-0.2	-0.4	7.0E-01	0.0
R_superiorparietal	-2.5	1.2E-02	-0.2	-4.4	9.1E-06	-0.3	-2.0	4.3E-02	-0.1	-3.8	1.5E-04	-0.3	0.0	9.8E-01	0.0	-6.9	1.0E-11	-0.7	-2.4	1.5E-02	-0.3	-2.3	2.1E-02	-0.3	-1.1	2.6E-01	-0.1
R_superiortemporal	-3.6	3.5E-04	-0.3	-8.1	1.2E-15	-0.6	-6.5	1.0E-10	-0.4	-6.3	3.5E-10	-0.6	-1.3	2.0E-01	-0.1	-2.1	3.5E-02	-0.2	-2.7	7.9E-03	-0.3	-0.4	6.9E-01	-0.1	-1.9	5.6E-02	-0.1
R_supramarginal	-0.8	4.0E-01	-0.1	-3.7	2.2E-04	-0.3	-4.9	1.3E-06	-0.3	-4.4	1.4E-05	-0.4	-0.6	5.3E-01	-0.1	-4.7	2.7E-06	-0.5	-4.1	4.7E-05	-0.5	-1.2	2.1E-01	-0.2	-1.9	6.0E-02	-0.1
R_frontalpole	0.2	8.3E-01	0.0	-8.3	1.1E-16	-0.6	0.5	6.3E-01	0.0	-1.9	6.4E-02	-0.2	-0.6	5.4E-01	-0.1	-0.4	7.3E-01	0.0	0.6	5.5E-01	0.1	0.9	3.9E-01	0.1	-3.7	1.9E-04	-0.2
R_temporalpole	3.0	2.5E-03	0.3	0.4	6.7E-01	0.0	-4.4	1.3E-05	-0.2	0.1	8.9E-01	0.0	2.2	3.1E-02	0.2	2.5	1.4E-02	0.3	0.8	4.1E-01	0.1	1.1	2.9E-01	0.2	-1.9	5.7E-02	-0.1
R_transversetemporal	-2.8	5.2E-03	-0.3	-3.9	8.6E-05	-0.3	-4.8	1.4E-06	-0.3	-3.7	2.3E-04	-0.3	-1.8	7.6E-02	-0.2	-4.5	6.0E-06	-0.5	-2.8	4.7E-03	-0.3	0.3	7.8E-01	0.0	-4.0	7.7E-05	-0.2
R_insula	-3.3	1.2E-03	-0.3	-7.2	6.9E-13	-0.5	-5.1	3.7E-07	-0.3	-6.1	1.7E-09	-0.5	-2.1	3.8E-02	-0.2	-0.5	5.9E-01	-0.1	-2.6	1.1E-02	-0.3	-2.7	6.9E-03	-0.4	-3.2	1.3E-03	-0.2



Supplementary Figure 1. High consistency between the case-control difference (i.e., effect size) brain map that sourced from (a) discovery sample and (b) validation sample. (c) It shows a highly spatial correlation (r=0.678, p=2.7×10<sup>-12</sup>) between discovery data and validation data.



(d) Gene enrichment in Biological Processes

database.



Supplementary Figure 2. Partial least squares (PLS) correlation analysis between individual deviation and human brain gene expression data. (a) Spatial map of the first component (PLS1) in the left hemisphere. (b) The spatial correlation between the PLS1 score and individual deviation in schizophrenia, measured by PDscore. (c) The ranked gene weights of PLS1 (FDR p < 0.05). (d) Top 20 gene ontology (GO) biological processes by enrichment analysis. Circle color: different biological processes. Circle size: number of genes. (e) Gene enrichment analysis in Cell Type Signatures. (f) Gene enrichment analysis in human disease-associated



**Supplementary Figure 3**. **Performance of network diffusion model (NDM) on estimating cross-sectional GMV differences in group-level patients with schizophrenia**. (a) Model performance is indexed by the Spearman correlation coefficient (*r* value) between observed values and estimated values across brain regions. (b) Model performance with each bilateral region as the source seed of NDM. The *r* values are mapped to a brain template to show model performance of each region being the NDM seed. Red stars represent the optimal seed region (bilateral) with best performance. NDM<sub>MC</sub>, morphological covariance connectome type-based NDM; NDM<sub>SC</sub>, structural connectome type-based NDM; NDM<sub>FC</sub>, functional connectome type-based NDM.